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Introduction: Newfoundland and Labrador (NL) has an increased incidence of 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is caused by a p.S358L 
mutation in TMEM43, the first symptom of which may be sudden cardiac death (SCD). 
When diagnosed and treated, mortality is significantly reduced. Primary care physicians 
(PCPs) are often the first point of health system contact for families affected by ARVC. 
PCPs acknowledge the importance of integrating genetics into their practice, but report 
uncertainty regarding appropriate counseling and referral strategies. Web-based tools can 
be effective education methods. This project aimed to create a tool designed to increase 
the likelihood of appropriate management and referral of persons at risk of ARVC caused 
by p.S358L in TMEM43. 
Methods: We used a multiple methods, iterative approach to develop an educational tool. 
This included initial creation, a working lunch with five PCPs, subsequent revision of the 
tool, use of pre-existing TMEM43 data providing additional family information and then 
further revision. It was distributed to a cohort of PCPs and Family Medicine Residents 
(n= 780) for feedback via an online survey containing nine Likert-scale questions, two 
qualitative questions and five demographic questions.  
Results: Initial feedback requested greater clarity on whom to refer to appropriate genetic 
and cardiac services. Pedigree information showed that 56%, 39%, and 31% of affected 
persons had at least one first-, second-, or third degree relative with a known history of 
severe cardiac problems at time of their initial presentation. This information was then 
integrated into the updated version of the tool, to ensure PCPs are prompted to ask about 




the final tool was provided by 43 online surveys completed by PCPs in NL. 
Overwhelmingly positive responses were noted. 
Discussion: Feedback from PCPs and multi-generational, historic pedigree information 
was used to create an educational tool for PCPs which may more easily identify those at 
risk for ARVC caused by the p. S358L mutation in TMEM43. Future research will 
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Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a genetic heart 
condition. Several genes are implicated in its etiology. A specific type of ARVC is caused 
by the p. S358L mutation in TMEM43 and is prevalent in the population of 
Newfoundland and Labrador (NL), Canada. This type of ARVC is highly lethal in 
affected individuals. It often causes sudden cardiac death (SCD) in undiagnosed 
individuals as young as 19 years old in males and 37 years old in females; the median age 
of death for males is 40 years and females is 67 years (Hodgkinson et al., 2016). To 
prevent SCD from occurring, primary care physicians (PCPs) need to correctly identify 
these individuals. This identification is essential as PCPs are the gate keepers to 
specialized care, such as cardiac and genetic services, and highly effective care is 
available to prevent SCD (Hodgkinson et al., 2016).  
The impetus for this thesis is the desire to assist PCPs to accurately ascertain those 
at risk of ARVC caused by the p.S358L mutation in TMEM43 before a catastrophic event, 
such as SCD.  
Currently, individuals and families who are known to carry the mutation are seen 
by cardiac and genetic specialists and undergo cascade screening. Cascade screening 
identifies all individuals at risk within a family tree. At risk individuals are identified by 
their level of relation to the original case of ARVC, otherwise known as the proband, and 
are thus assessed and offered further screening (Definition of cascade screening-NCI 
Dictionary of Genetics Terms). The problem remains, however, that new families are 




previously unknown family.  
This thesis will explore one method to increase the likelihood of determining at 
risk families, prior to an SCD occurring. The way we have chosen to do this is to develop 
an educational tool to inform PCPs about this type of ARVC. The methodology we will 
use to accomplish this is as follows: (a) the creation of a draft tool utilizing past expertise 
and data from a long standing ARVC project and dataset (HREB 00-76), (b) input from a 
small group of PCPs in a focus group and (c) modification of the tool via input from 
PCPs and /or PCP residents to obtain a final product. 
This thesis discusses ARVC as a general disease, as well as ARVC caused by 
p.S358L in TMEM43 prevalent in NL. It provides a review of the use of multi-
generational family histories, educational tools in primary care, and genetics and 
genomics. It is my hope that the tool created through this thesis will help PCPs identify 
patients who may be at risk for ARVC as well as those at risk for other forms of SCD. 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
 While all cardiovascular disorders have a genetic component, some can be further 
identified as Mendelian disorders. These types of cardiovascular diseases occur when one 
mutation in a single gene is inherited through an affected family member, causing the 
disease. Mendelian disorders are often identified because of the pattern of disease seen in 
family trees.  Included in these disorders are inherited cardiomyopathies such as: 
hypertrophic cardiomyopathy (HCM), familial dilated cardiomyopathy (FDCM), and 
arrhythmogenic right ventricular cardiomyopathy (ARVC) (Ingles et al., 2013).  These 
cardiomyopathies are all heart muscle disorders, which are characterized by structural and 




forms of ARVC are caused by a mutation that occurs in a non-sex chromosome, where a 
single copy of the mutation is required to cause the disease in affected individuals. The 
pattern seen in families for this disease is vertical, or from parents to offspring. Therefore, 
it occurs across generations from affected parents to affected offspring (Rogers, 2019).  
Comparatively, in autosomal recessive diseases, the same mutation from each parent must 
be inherited for the disease to be expressed, which is seen in a cardiac disease such as 
Naxos disease, a recessive form of ARVC. It is important to note that Naxos disease 
presents as a horizontal pattern of inheritance, so the disease is seen in sibships (brothers 
and sisters) only (French, 2008; Rogers, 2019). 
ARVC is defined pathologically by the replacement of cardiac muscle tissues in 
the right or left ventricle of the heart with fibrous and fatty tissue. As the ventricles are the 
main pumping chambers of the heart responsible for (a) pumping oxygenated blood to the 
body (left side), and (b) pumping oxygen depleted blood to the lungs (right side) 
(Redington et al., 2009), the replacement of the normally strong cardiac muscles with 
fibro-fatty tissue can cause numerous complications. One of these complications arises 
from the development of life-threatening ventricular tachyarrhythmia (VT). This arises 
(as the name implies) in the ventricles, which can cause a resting heart rate of greater than 
300 beats per minute. VT is caused when an electrical conduction path of the heart, which 
controls the beating, is blocked, or slowed down. This can cause the electrical impulses of 
the heart to fire incorrectly, or erratically (Tung et al., 2010). Symptoms of VT include 
heart palpitations, presyncope (light headedness), syncope (fainting), and dizziness (René 
& Jackson, 2002). When VT becomes too fast, the heart is unable to maintain the speed at 




results in ventricular fibrillation (VF). VF will then cause SCD, as the heart is failing to 
beat in a purposeful manner; oxygen is not perfusing to the body, and inevitably the heart 
stops (René & Jackson, 2002). SCD accounts for about 50% of all deaths with a 
cardiovascular cause (Myerburg et al., 1997), with about 20% of these deaths caused by 
an inherited genetic cardiomyopathy (Zipes & Wellens, 1998).  
The first systematic description of ARVC was from Marcus et al.,  in 1982, where 
a possible familial effect was identified. ARVC was initially called pre-excitation 
syndrome (Fontaine et al., 1977). It was later referred to as a dysplastic disorder 
(abnormal growth and development of cells) (Frank et al., 1978). This later expanded to 
include an arrhythmic factor, subsequently identified as arrhythmogenic right ventricular 
dysplasia (ARVD) (Fontaine et al., 1982). In 1996, the disease was recognized as a 
cardiomyopathy, effectively changing the name to that with which it is currently known, 
ARVC (WHO/ISFC, 1996). Since the recognition of ARVC in 1996, 12 Mendelian 
autosomal dominant forms of ARVC have been identified and numbered in the order of 
their discovery: ARVD1-ARVD12 (Hodgkinson, 2009).  
Natural History of ARVC 
 The natural history of a disease is defined as the symptom presentation seen in an 
affected individual from birth until death (Raina, 2016). The natural history of ARVC has 
traditionally been separated into four stages. In the first (concealed) phase, affected 
individuals are normally asymptomatic but subtle changes to the structure of the right 
ventricle may be present that may or may not cause an arrhythmia. SCD can occur in this 
stage, as the first manifestation of the disease. The second stage results in obvious 




ventricular structural and functional abnormalities. Ventricular arrhythmias are prominent 
during this stage. In the third phase, there is a progression and extension of muscle 
disease, known as the global right ventricle dysfunction phase. Contractions of the heart 
may be impaired in this stage and isolated right heart failure may be present. The final 
stage results in bi-ventricular pump failure as well as obvious left ventricular failure, 
which can lead to congestive heart failure (CHF) and other complications (Corrado et al., 
2000). These stages are seen in all forms of ARVC, regardless of underlying mutation or 
locus and are often fluid and variable in their manifestations (as discussed below).  
Variable Expression and Reduced Penetrance. 
 As ARVC is an autosomal dominant disorder, variable expression and reduced 
penetrance occurs. Variable expressivity occurs when the same disease, caused by the 
same mutation, affects related individuals in different ways (Genetics Home Reference-
NIH, 2019). Some individuals may show many clinical symptoms, while others show 
few. Therefore, diagnosed ARVC in one family member can look very different than in 
another. Likewise, reduced penetrance is an extreme form of variable expression, in that 
the presence of the gene mutation in one family member may not result in any clinical 
presentation of the disease in another affected family member (Genetics Home Reference-
NIH, 2019). All autosomal dominant disorders seem to demonstrate variable expressivity 
and reduced penetrance (Azaouagh et al., 2011; & Hodgkinson, 2009). Notably, though, 
for many newly described autosomal dominant disorders, there are not enough data to 
robustly define the extent of variability or level of penetrance (Dr. K. Hodgkinson, 
personal communication, November 20, 2018). 




 1994 Criteria  
In 1994, leading cardiologists collaborated and provided expert opinions of 
ARVC. Subsequently, diagnostic criteria for ARVC were defined. Cardiologists identified 
major and minor criteria, some of which had to be met for an ARVC diagnosis (McKenna 
et al., 1994). The main classes of heart irregularities assessed as part of the criteria were: 
dysfunction and structural abnormalities, histological changes, repolarisation and 
depolarisation abnormalities, arrhythmias, and family history (FH). Features of each class 
were defined and separated into major and minor criteria. To meet a diagnosis of ARVC, 
an individual would have to present with two major, or one major plus two minor, or four 
minor criteria (see Appendix A).  
Critiques of the criteria identified that individuals were only diagnosed when 
presenting with symptoms severe enough to necessitate medical attention, resulting in an 
ascertainment bias. Therefore, there was a gap in diagnosing individuals who: (a) had the 
disease and had not sought medical attention, and (b) those who died from the disease 
prior to any medical attention.  
2002 Criteria 
Because of the advancements made in clinical test modalities and the 
identification and assessment of at risk relatives who manifested clinical features and who 
did not meet the diagnostic criteria of 1994, the diagnostic criteria were modified in 2002. 
In the updated criteria (see Appendix A), fewer clinical features were required for 
diagnosis of a relative when there was a known family member affected by ARVC 
(Hamid et al., 2002). Families were identified by clinical presentation of the disease, 




cardiac clinical symptoms, which may not have been a part of the existing diagnostic 
criteria in place at that time (Hodgkinson, 2009). 
Limitations still existed with the 2002 criteria, however, including failure to 
recognize deceased individuals who had ARVC. While autopsy results might have 
proposed a cause of death as ARVC, there was a lack of confirmation of the diagnosis.  
Failure to recognize those at risk for ARVC had and continues to have potentially 
severe consequences, given the linkage of SCD and ARVC. Due to limitations of the 2002 
diagnostic criteria, individuals and families could have been living unknowingly with 
ARVC. The disease and associated threats could be passed on to a population that has no 
knowledge it is at risk (Merner, 2011).  
2010 Criteria 
In 2010, Marcus et al. provided a further update to the diagnostic criteria. They 
incorporated advances made in diagnostic imaging, including 2D Echocardiogram 
(ECHOs) and magnetic resonance imaging (MRIs), as well as genetic information (see 
Appendix A). The updated criteria improved diagnostic sensitivity (the number of people 
who have ARVC and who are identified positively), while maintaining diagnostic 
specificity (those who do not have ARVC and are correctly identified as such) (Saah & 
Hoover, 1997). New quantitative parameters were set; however, a similar approach of 
classifying structural, histological, electrocardiography (ECG), arrhythmic, and genetic 
features of the disease as major and minor criteria remained (Marcus et al., 2010).  
While these changes to the diagnostic criteria are pivotal to the diagnosis and 
treatment of those with ARVC, there is still the potential for bias to exist when 




technology to test as required by the new diagnostic criteria. There should be an 
acknowledgement that individuals and their family members in these areas may not be 
properly diagnosed, nor in a timely manner, potentially resulting in a selection bias. The 
2010 criteria also included genetic mutation analysis. Inclusion of genetic mutation 
analysis helped with sensitivity, but the clinical repercussions of mutations are not fully 
understood, due to ascertainment bias, as often those with genetic mutations are the only 
group studied.  
Clinical tests for ARVC. 
There are several cardiac clinical tests that can be used to test for ARVC. 
12-Lead Electrocardiography (ECG). 
ECGs test for abnormalities in the electrical activity of the heart. Electrodes are placed 
strategically on the chest and heart activity is translated to waves that are traced to paper. 
This test can measure if electrical impulses are sent through the heart too fast, slow, or 
irregularly. This test is easy, inexpensive, and available in many health centers (DiMino et 
al., 2013). 
The signal-average ECG (SAECG). 
 SAECG are similar to ECGs but are more detailed. The SAECG collects 
“average” heartbeat data. The test captures about 500 beats of the heart, then sums the 
components of the heartbeat to come up with an “average” heartbeat. This test identifies 
subtle abnormalities present in the normal heart rhythm, known as “late potentials”, 
which are indicative of arrhythmias, including VT (Cain et al., 1996). 
The Holter Monitor. 




recorded for the duration the monitor is worn and stored in a device worn by the 
individual being tested. During the time that patients are wearing the monitor, they are 
asked to complete a diary where they are to note any symptoms they feel. Information 
such as the time the patient experiences a symptom, as well as what they were doing 
when the symptom presented itself, are used in collaboration with the data obtained from 
the monitor (Maron et al., 2003). The Holter Monitor can measure Premature Ventricular 
Contractions (PVCs), which are extra heart beats that begin in one of the two lower 
chambers of the heart. These extra beats can disrupt the heart’s normal rhythm. This can 
lead to arrhythmias and weakening of the heart muscle (Mayo Clinic, 2019). The number 
of PVCs seen during a 24-hour Holter Monitor has been shown to be the best clinical test 
in predicting if an individual has ARVC caused by the p. S358L mutation in TMEM43.  
Echocardiography (ECHO). 
An ECHO is an ultrasound of the heart, which produces sound waves that create 
pictures of the heart’s chambers, valves, walls and blood vessels. The ECHO provides an 
accurate picture of the heart’s structure and function through measurements of the heart’s 
chambers, function of the valves, and effectiveness of the ability of the heart to pump 
(that is, the ejection fraction or how much blood is leaving the heart when it contracts). It 
can also detect abnormal movements of the heart muscle and valves, which is pertinent 
when examining for potential heart conditions (Mankad, 2016; & Nicoll et al., 2012). 
Ultimately, they can provide an accurate measure of the movement and efficiency of the 
heart (Blanchard & DeMaria, 2013). ECHOs are also widely available; however, they 





During a cardiac biopsy, tissue is removed from the heart while the individual is 
alive. The tissue is examined for the presence of fat and fiber. This test is limited in 
diagnosing ARVC, however, in that the sample may be taken from an area of the heart not 
yet impacted by ARVC, therefore yielding an incorrect diagnosis. There are also 
complications associated with this procedure, including cardiac perforation and electrical 
complications, such as arrhythmias, that may lead to death (Liang et al., 2014). 
Magnetic Resonance Imaging (MRI). 
MRIs offer a less invasive method for examining the heart for presence of fat and 
fiber. Signals are sent through the heart, and tissue density is determined through 
comparison of signals sent through normal heart muscle. Fat and fibrous tissue increases 
signal density, while normal heart tissue decreases signal density. Access to an MRI can 
be a challenge for patients, particularly those in rural areas, as MRI machines are not 
always available in these hospitals and health centers (Bogaert et al., 2011). Other 
considerations include that MRIs can be problematic for those over a certain weight and 
for those with claustrophobia.  
Treatment of ARVC. 
Three treatment options exist for ARVC, none of which cure the disease but try to 
make living with it more manageable. Antiarrhythmic drug therapies are prescription drug 
interventions that aim to prevent fatal arrhythmias, though often they have significant side 
effects. Catheter ablation involves burning, or destroying, a small section of the heart 
muscle.  This creates a scar that disrupts the area in which the electrical signals in the 
heart have been blocked or slowed down, which results in the individual experiencing VT. 




heart can beat correctly again (Tung et al., 2010).  
The most successful intervention has been the implantable cardioverter 
defibrillator (ICD). The ICD is typically placed in the upper left-hand side of the chest. 
From the ICD, wires are run which are fed through the venous system into the heart. 
Usually the placement and location of an ICD are the same as a pacemaker. The ICD is a 
battery-operated device which monitors the heart rhythm and shocks the heart when 
abnormal rhythms are detected. This prevents SCD by bringing the heart back into a 
normal rhythm. Prior to a shock discharge, an ICD can pace the heart back to a normal 
rhythm. If this pacing fails to correct the heartbeat, a shock then occurs. The success of 
ICDs was determined early through randomized controlled trials (RCTs).  Through these 
trials, the effectiveness of ICDs was compared to antiarrhythmic drugs in patients who 
survived life-threatening VT, often following a myocardial infarction, and were at risk for 
further lethal events that could cause SCD (Antiarrhythmics versus Implantable 
Defibrillators (AVID) Investigators, 1997). ICDs were found to be superior in treating 
these individuals as compared to antiarrhythmic drugs.  
Acknowledging the success of ICDs evident in the literature, Corrado et al. (2015) 
reported that any further RCTs that examined the ability of antiarrhythmic drugs versus 
ICDs in treating those with a history of, or potential for, VT would be unethical. Corrado 
et al. (2015) also reported that ICD treatment for ARVC patients who experienced VT 
should be the treatment option of choice. Similarly, Boriani et al. (2007) demonstrated 
that “ICD implantation is highly effective for prevention of sudden death in ARVC,” (p. 
184). Evidence justifying the implantation of an ICD in high risk ARVC patients was also 




firings of the ICD (instances where a patients VT would have turned into a fatal VF) 
confirms the life-saving efficacy of prophylactic ICD therapy - one fourth of patients 
received correct, lifesaving ICD firing. 
Though very effective, ICD placement is not risk free and has potential side 
effects such as risk of infection, inappropriate firing, and an increase in morbidity and 
mortality (Ingles et al., 2013). Inappropriate firings occur when the ICD shocks the heart 
in the absence of an abnormal rhythm. According to Shenoy et al. (2016), incorrect ICD 
firings have occurred from “external electromagnetic interference from electrocautery, 
welding, acupunctures, low-output transcutaneous electric nerve stimulators, and 
electronic muscle stimulators” (p. 139) as well as device dysfunction. This can have 
serious physiological and psychological impacts on the individual who experiences these 
inappropriate firings.  
Prevalence. 
While ARVC has been reported worldwide (Cho et al., 2007; Fung & Sanderson, 
2001; Kaartinen et al., 2007; & Perzanowski et al., 2000), the prevalence and incidence 
rates are in effect unknown. Prevalence, referring to the number of cases at a single point 
in time, and incidence, referring to the number of cases over a specified period, require a 
definitive diagnosis, which is problematic with ARVC due to the difficulty in making a 
positive clinical diagnosis (Corrado et al., 2000). In Italy, where many ARVC studies have 
been conducted, the prevalence is reported as 1/5000, and it is assumed to account for 
20% of all deaths in young adults (Thiene et al., 1988). Another Italian study reported an 
incidence of 6/10,000 (Rampazzo et al., 1994). In the USA, one study suggests that 17% 




al., 1995). In France, 36% (18 out of 50) of cases of sudden perioperative death were 
considered to be caused by ARVC in seemingly healthy individuals (Tabib et al., 2000). 
ARVC caused by the p. S853L mutation in TMEM43. 
Specific to this thesis is the genetic sub-type of ARVC caused by the p. S358L 
mutation in TMEM43. The disease was first recognized in NL in the 1970s as a familial 
disorder that caused SCD in young males (Guiraudon et al., 1983). In 1998, using 
Newfoundland families, linkage studies determined the likely locus for this gene was on 
the short arm of chromosome 3 (Ahmad et al., 1998). This helped narrow down the 
location of the mutation. In 2008, a research team at Memorial University in NL located 
the p. S358L mutation in TMEM43 (Merner et al., 2008).    
ARVC caused by the p. S358L mutation in TMEM43 is prevalent in NL. 
Currently, 27 families have been found to have disease caused by p.S358L in TMEM43 
(K. Hodgkinson, personal communication, February 3, 2020). The prevalence of ARVC 
caused by TMEM43 p.S358L in NL is estimated to be about 1/500 to 1/1000 individuals 
(Etchegary et al., 2015). 
As a result of this research, a working database has been established which 
contains pertinent and valuable information on individuals affected by ARVC caused by 
the p. S358L mutation in TMEM43. The SCD research team maintains this database 
containing in-depth information on over 1000 people (across generations) from 27 
families in the province. The database contains demographic and clinical variables 
relevant to research and ongoing clinical care. 
In affected individuals, the age of cardiac complications occurs earlier than those 




females and with younger ages of death than affected females. Heart failure is seen in 
16% of affected males by 40, and 46% in males by age 60. Holter Monitor testing is the 
only test able to clinically diagnose disease prior to death. PVCs greater than 200 in 24 
hours are seen in affected males by a median age of 25, while in females, the median age 
is 48 years. Median survival in affected males is 40 years (Merner, 2008).  
While females are affected by this specific type of ARVC, clinical manifestations 
and death are delayed and do not occur at such an early age. Females have a later onset of 
symptoms, fewer hospitalizations, and longer survival (median age of death 67 years). 
When looking at clinical data, with the exceptions of syncope and palpitations, there is no 
difference in symptoms between affected and unaffected females (Hodgkinson et al., 
2013). 
Treatment of ARVC caused by the p. S358L mutation in TMEM43. 
As determined early in the literature (Hodgkinson et al., 2005), the effectiveness 
of ICDs in families in NL who were linked to having ARVC, was proven successful. They 
identified that ICDs had a positive impact on survival for males with ARVC. At this point, 
the mutation had not been discovered, so clinical descriptions regarding the ICD were 
made based on research haplotype results. In 2016, using mutation analysis, long-term 
evidence for ARVC caused by the p. S358L mutation in TMEM43 was provided based on 
the success of ICDs.  Hodgkinson et al. (2016) identified that males with ARVC caused 
by the p. S358L mutation in TMEM43 who received an ICD obtained “a significant and 
substantial survival benefit” (p. 5), with females obtaining a significant effect as well. 
Males who had a history of VT/VF and were treated with ICD placement had a 95% 5-




100% 5- year survival rate. This is comparable to 65% and 50% survival rate, 
respectively, of controls who did not receive an ICD. In females, there was a 97% 5-year 
survival rate found in those with an ICD, compared to 85% in controls. This data equates 
to an increase in life expectancy by 30 years for affected males who had been provided 
with an ICD based on the genetic mutation alone (Hodgkinson et al., 2016). 
Psychosocial impact of living with an ICD. 
While the success of ICD therapy cannot be ignored in increasing survivability for 
those with ARVC, it is important to highlight research which gives insight to the 
psychosocial impacts of living with an ICD. Recent evidence from Etchegary et al., 
(2017) reveals some of the psychosocial burdens of living with an ICD. This study 
interviewed individuals who were mutation positive, mutation negative and their 
spouses/partners and found four major themes in their qualitative analysis:  
(1) Acceptance and gratitude. Across participants, it was clearly shown that the 
survival benefits of having an ICD were understood. This was especially true in families 
in which a young family member died due to SCD or in cases where an ICD appropriately 
fired, thus saving an individual’s life.  
(2) Grudging acceptance. While the benefits of having an ICD were recognized, 
acceptance of needing an ICD took time, and often came with a sense of resignation.  
(3) Psychological effects. Emotional and psychological well-being were identified 
as being negatively affected by mutation carriers, mainly due to the constant awareness of 
the ICD and subsequent negative recurring thoughts causing anxiety, depression and fear. 
Fear and doubt were reflected by all participants, particularly their spouses. Survivor guilt 




relationship difficulties were expressed by participants as well. Anxiety around the fear of 
the ICD firing caused feelings of isolation and negatively impacted social relationships.  
(4) Practical concerns. Clothing and travel choices, ability to drive, and 
continuation of recreational activities were all concerns identified by participants.  
These findings were in line with quantitative research that reported individuals 
who had inherited cardiomyopathies and were fitted with an ICD reported higher rates of 
depression and lower Quality of Life scores (QOL) as compared to those who received an 
ICD for ischemic or valvular heart disease (Jacq et al., 2009). 
These issues may be minimized by clinicians, who understandably focus on the 
clinical aspects of ICD management rather than focusing on the psychological, social, and 
economic impact of living with an ICD. Psychosocial outcomes might be improved or at 
least better managed if psychological screening and counselling were provided pre-
implantation, and psychological services were broadened to include unaffected family 
members and spouses of affected individuals (Etchegary et al., 2017; Manuel & Brunger, 
2016). 
The multitude of psychosocial issues that can be experienced by families affected 
with ARVC highlights additional issues of importance for clinicians in primary care who 
are often the first point of contact with affected individuals. Incorrect referrals or not 
referring high risk individuals to cardiology and genetics divisions have implications not 
only for clinical outcomes, but also a host of psychosocial and familial impacts. 
Importance of Establishing Multi-Generation Family Histories in Primary Care 
Obtaining family histories is one of the core competencies and roles of a PCP 




family histories has been identified by PCPs (Carroll et al, 2016b; & Wilson et al., 2016). 
However, it has been demonstrated that PCPs have concerns obtaining and interpreting 
FH including: issues with what information to include in the FH, how to integrate 
obtaining FH information within the patient’s primary care visit, and integrating FH 
information into electronic health records. Other reported issues with obtaining accurate 
FH include the dependence on patients to self-report their own FH (Mikat-Stevens et al., 
2015).  
 Regardless of the concerns raised by PCPs on how to obtain and interpret accurate 
FH, the literature demonstrates the importance of obtaining multi-generation family 
histories and its importance in providing holistic care to patients. Waddell-Smith et al. 
(2016) identified that with multi-generational FH taking, inherited diseases clearly 
become highlighted through cascade screening. Waddell-Smith et al. (2016) found that it 
was possible to detect eight to nine affected family members of a genetic heart condition 
when employing family cascade screening for family members identified though FH, 
though typically two to four affected family members are detected. These individuals are 
often otherwise asymptomatic. This translates to 25-40% of asymptomatic individuals 
who are at risk of having the genetic heart condition being detectable though use of FHs. 
Furthermore, the importance of multi-generational FH was echoed by Dunn et al. (2013), 
who commented that multi-generational FHs are critical when considering diseases which 
may vary in symptom presentation or may seemingly “skip generations” due to their non-
penetrance. Dunn et al. (2013) demonstrate the importance of multi-generational FH in 
identifying affected family members who are undiagnosed and may be affected but are 




identifies those at risk for a specific condition. It also removes those who may be at risk 
but do not have the disease in question. This individual’s descendants are removed from 
testing, limiting the need for unnecessary clinical investigations. Cascade screening also 
limits the unnecessary use of expensive medical equipment, unnecessary hospital visits 
and appointments, and helps ensures that those in need have timely access to services and 
equipment for testing (Dunn et al., 2013).  
 ARVC can present with variable expression in affected family members 
(Azaouagh et al., 2011; & Hodgkinson, 2009). Therefore, the disease may not present and 
progress the same in all affected family members. A multi-generational FH will enable an 
accurate snapshot, which reflects not only disease and death, but also other symptom 
presentation. 
 Family Pedigrees. 
Family pedigrees (see Appendix B) are a graphic depiction of a family’s medical 
history. Integrating symbols into the diagram, which represents specific information such 
as sex, birth relation, and degree of relatives, they help inform health care providers on an 
individual’s risk of certain illnesses and other conditions. In addition, certain medical 
conditions and the individuals they affect are documented within the pedigree (Bennett, 
2019). Family members represented in the pedigrees ideally will go back at least three 
generations, and include parents, aunts, uncles, cousins and grandparents. Within the 
pedigree, males are typically depicted with a square, females with circles, and people of 
unknown sex as diamonds. Death of an individual is shown with a diagonal line across 
the symbol, with age or year of death follow the notation “d.” Marriage or mating couples 




connected with vertical lines (Craft-Rosenberg & Pehler, 2011). From these depictions, 
first-, second-, and third-degree relatives can be determined. First-degree relatives consist 
of parents, children, and siblings; second-degree relatives are aunts, uncles, nieces, 
nephews, and grandchildren; and third-degree relatives are first cousins, as well as great-
grandparents, great-grandchildren, and great aunts and uncles (Sadovnick & Macleod, 
1981). As ARVC is an autosomal dominant disease, it is pivotal that this information be 
obtained in order to determine risk of inheriting the disease.  
Use of Genetics and Genomics in Primary Care 
 As ARVC is a genetic disease, it is integral to discuss the role of genetics and 
genomics medicine in further advancing the understanding, recognition, and treatment of 
this disease. The integration of genetic and genomics medicine into primary care has 
grown in recent years (Melo et al., 2015). Advances in genetics and genomics offer an 
enhanced understanding of diseases and allow for more individualized, patient centered 
care. With this enhanced understanding, prevention and treatment of diseases takes 
individual differences into account, blending genetic and genomic information together 
with clinical care. For the full benefits to be reaped from this collaboration, patient-
centered care, or precision medicine, needs to be fully integrated into primary care 
(Carroll et al., 2016b). 
  While evidence indicates that PCPs do acknowledge their role in providing initial 
genetic risk assessment and counselling to their patients (Wilson et al., 2016), PCPs have 
identified several challenges and concerns regarding this integration. This includes a lack 
of confidence in referring and counselling patients at risk for, or diagnosed with, a genetic 




genetics and genomics medicine. As such, PCPs have identified that they feel inadequate 
in fulfilling their growing role with the integration of genetics and genomics medicine 
into primary care (Mikat-Stevens et al., 2015). The complex nature of knowing who to 
test for a genetic condition, the appropriate time to test them, recognizing triggers that 
indicate a need for genetic counselling and testing, the appropriate test to use, and how to 
interpret the results all present compounding concerns that must be considered by PCPs. 
Additionally, once a genetic condition is confirmed, treatment provided by PCPs must 
integrate this diagnosis into primary and acute care provided to the patient (Carroll et al., 
2016b; & Scott & Trotter, 2013). PCPs have identified barriers in accessing recent, 
relevant knowledge about specific genetic conditions in general (Carroll et al., 2016b), as 
well as professional standards and guidelines on testing patients at risk for genetic 
conditions (Mikat-Stevens et al., 2015). Additionally, lack of personal connections within 
genetics medicine and PCPs have left PCPs feeling like they are referring patients into an 
“abyss”, with little interaction, and guidance (Carroll et al., 2016b). Furthermore, Carroll 
et al. (2016b) identified that PCPs may not be aware of their incorrect assumptions and 
beliefs, or lack of knowledge, of genetics and genomics and the restriction this places on 
further integration. 
 In addition to the expression of overall lack of knowledge, skills, experience, and 
access to information, PCPs have also identified ethical concerns in the integration of 
genetics and genomics into primary care. Carroll et al. (2016b) reported that PCPs 
expressed concern over the impact of the doctor-patient relationship with increasing 
integration of genetic and genomic medicine. PCPs explained that patients trust them as 




value the input of PCPs in the decision-making process of testing for a specific disease. If 
PCPs cannot be relied upon to provide accurate information in that decision-making 
process, the question remains as to who will. 
The potential for increased patient anxiety and psychological distress over testing 
and confirmation of the presence of a genetic condition has been identified in the 
literature (Mikat-Stevens et al., 2015). Coinciding with this is the potential impact genetic 
testing could have on both social and insurance discrimination. PCPs reported concerns 
over the impact of positive tests on patients’ ability to access medical insurance, as well 
as patients’ inhibition to get genetic testing done over their own fears of the negative 
impact it would have on accessing insurance (Mikat-Stevens et al., 2015). However, 
current legislation in the United States, set forth in the Genetic Information Non-
discrimination Act in 2008, limits discrimination in health insurance and employment that 
may be caused by genetic testing and subsequent results (U.S. Congress, 2008). In 
Canada, Bill S-201 (Genetic Non-Discrimination Act) was passed into law on May 4, 
2017 (Parliament of Canada, 2017). This law prohibits any person from requiring an 
individual to undergo genetic testing, or disclosing of any genetic testing result “as a 
condition of providing goods or services to, entering into or continuing a contract or 
agreement with, or offering specific conditions in a contract or agreement with, the 
individual.” Notable exceptions exist, such as for health care providers and researchers. 
The law also relates to the Canada Labour Code, which protects employees from being 
required to have a genetic test done or disclose the result of a genetic test, as well as the 
Canadian Human Rights Act which prohibits discrimination based on genetic 




Suggestions on how to improve the integration of genetics and genomics medicine 
into primary care offer a pathway for bridging the gaps expressed by PCPs. Carroll et al. 
(2016b) reported that increasing PCPs’ knowledge about genetics and genomics medicine, 
increasing their accessibility to genetic specialists, and having reliable and relevant 
resources available at the point of care were potential solutions to increasing PCPs’ 
confidence with, and knowledge of, the integration of genetics and genomics medicine 
into primary care. Furthermore, continuing medical education programs and interactive 
educational interventions have been proposed as cost-effective ways to facilitate the 
integration of genetics and genomics medicine into primary care (Wilson et al., 2016). 
Use of Educational Tools in Primary Care 
 Giving consideration to the concerns and issues acknowledged previously, there is 
an identified need to provide PCPs with information on how to best integrate genetics and 
genomics medicine into family medicine, improve overall knowledge, increase the 
identification of those affected by a genetic condition and refer them to appropriate 
services, and provide evidence based findings so that those who are referred to genetics 
services are done so properly (Carroll et al., 2011). Printed educational materials have 
been identified as a common way to communicate important health information to PCPs 
that is relatively low cost (Genova et al., 2014; & Grimshaw et al., 2014), and improves 
overall knowledge (Williams et al., 2015). 
 Printed educational materials can vary, and may include monographs, articles in 
peer-reviewed journals, and clinical guidelines (Farmer et al., 2008). However, for the 
material to be effective, the information within them must be interesting and easy to 




2014). Readability, content, organization, tone/language, illustrations, 
appearance/topography, and appeal have all been identified as important areas of focus to 
increase uptake of printed educational materials, ensuring that those areas are reflective to 
the intended audience (Williams et al., 2015). 
 As reported by Watson et al. (2001), some studies have shown that written 
guidelines can be helpful to PCPs; however, printed materials alone may have little 
impact on disseminating new knowledge, and subsequently, changing practice. 
Improvements in care offered by PCPs after an intervention of printed materials are on-
par with more expensive interventions such as academic outreach (Zwarenstein et al., 
2014). Evidence does indicate that an integration of educational tools and other 
knowledge translation efforts such as interactive workshops, produce the greatest impact 
on PCPs’ knowledge, confidence, and skills, as well as integration into practice (Carroll, 
et al., 2011; Williams et al., 2015).  
Project Overview 
 This project sought to create a simple, easy to use, paper-based educational tool to 
be used by PCPs to identify those at risk for carrying the TMEM43 p.S358L mutation for 
ARVC as well as their family members. To achieve this, we sought initial feedback from 
a small group of PCPs using a rough draft of the tool, then integrated their feedback to 
create a revised tool. The revised tool was sent to a larger group of practicing PCPs and 
Family Medicine Residents in the Faculty of Medicine, Memorial University, in NL.   
Genetics and genomics medicine have been increasingly integrated within primary 
care for some time. Gaps in knowledge and practice, however, have been identified by 




identified as cost-effective methods to increase medical health care knowledge on specific 
topics in PCPs. Acknowledging this, as well as the previously discussed importance of 
identifying those with the p.S358L TMEM43 mutation early, a simple two-page 
educational tool was created specifically for PCPs to utilize in their practice.  
The goal of this project was tool creation. The motivation for this work was to 
integrate patient-orientated experiences with supporting academic literature. The author 
of this thesis has been living with ARVC since being diagnosed in 2007 after a sibling 
suffered from sudden cardiac arrest (SCA). While it was suspected for decades that the 
family suffered from a genetic heart condition, it was not until the sibling’s SCA, and 
identification of the mutation by the team at Memorial University of Newfoundland, that 
a diagnosis was provided to the family. It is hoped that through the tool creation, 
individuals and families within the province who unknowingly have this condition can be 
more easily identified before a tragic event, such as SCA, or worse, SCD, occurs. 















 This project was completed over several stages and utilized a multiple methods 
approach to develop the final version of the tool for PCPs. The stages included: 
 Initial tool development using working knowledge from practitioners, and the 
existing 'ARVC caused by p.S358L in TMEM43' database  
 A working lunch with PCPs to obtain feedback on the first draft of the tool 
 Incorporating feedback from the working lunch to revise the tool; and,  
 Providing an opportunity to review the revised tool and offer feedback via an 
online survey distributed through an e-mail invitation to all PCPs and Family 
Medicine Residents in NL. 
Stage 1 - Initial Tool Development 
Based on the team’s clinical experience, as well as current guidelines for 
screening and referring individuals at risk for ARVC (Gollob et al., 2011), a draft 
educational tool on ARVC caused by the TMEM43 p. S358L mutation was developed as 
a three-page Word document (see Appendix C). 
Information in the initial draft of the tool included an introduction to SCD, ARVC 
as a genetic cardiac disorder in general and ARVC caused by the TMEM43 p. S358L 
mutation specifically, treatment options for those confirmed to have this specific type of 
ARVC, as well as important points to consider in determining an individual’s risk for this 




The first draft of this tool was loosely modelled on national ‘GEC-KO On the 
Run’ tools for healthcare providers practising in Canada, created by the Genetics 
Education Canada Knowledge Organization Centre (GECKO). These are freely available 
online (http://geneticseducation.ca/), and are written by healthcare teams comprising 
PCPs, geneticists, genetic counsellors, and genetic researchers. Genetic topics covered by 
GECKO knowledge translation tools are broad, but all are meant to aid in the translation 
of genetics into primary care, with a goal of increasing appropriate referrals to genetic 
services and decreasing wait times. Tools are short, but provide a concise summary of 
genetic disorders, technologies, and red flags for referral from primary care. Tools are 
reviewed by family physicians and include scholarly, referenced research. Topics covered 
by these tools include BRCA1 and BRCA2, Huntington Disease, Hypertrophic 
Cardiomyopathy and newborn screening, amongst several others. Information found 
within these two-page PDF files include an introduction to the disease in question, 
considerations to make in determining if a patient is at high risk for the disease, including 
genetic testing, and treatment methods, including clinical test results. The initial draft of 
the ARVC educational tool for the current study was modeled loosely on the 
Hypertrophic Cardiomyopathy tool (Honeywell et al., 2014). Similar concepts found 
within this ARVC tool and comparable models, such as that from Honeywell et al. (2014) 
include an overview of ARVC, specifically the type of ARVC of focus in this thesis, 
common red flags seen in this condition, information on genetic testing, and interpretation 
of genetic test results. Unique information found only within the ARVC tool include 
clinical testing information and the demonstrated importance of obtaining accurate family 




Stage 2 - Working Lunch with Physicians 
 When the draft tool had been reviewed by the SCD research team: Drs. Kathy 
Hodgkinson, Holly Etchegary, Sean Connors and Ms. Fiona Curtis (genetic counsellor), a 
working lunch with PCPs was scheduled in May 2016 at Memorial University’s St. Johns 
campus with the goal being to present the initial tool and obtain immediate feedback.  
 Recruitment of PCPs for the working lunch. 
 SCD team members used their personal and professional networks and contacts to 
invite PCPs to the working lunch. With this convenience sampling, no demographic or 
practice factors were considered in the selection process. Rather, the goal was to assemble 
a small group of PCPs – whatever their practice environment, years in practice, sex, age, 
etc., in order to begin the process of obtaining initial feedback. Those who expressed an 
interest in the lunch but could not make the date were given the option of receiving the 
tool via email and invited to provide their feedback through that medium. PCPs affiliated 
with Memorial University’s Faculty of Medicine in NL, as well as Family Medicine 
Residents, were also sent an e-invite (see Appendix D) to attend the working lunch 
through a Family Medicine list-serve at the Faculty of Medicine, Memorial University. 
Family Medicine Residents were thought to be key stakeholders for this project, as they 
would be the PCPs that would be working with families and individuals at risk for ARVC 
as practising PCPs in the near future.  
 Based on the literature, the team aimed for a response rate of six to eight PCPs 
(Bloor et al., 2001) for the working lunch.  




 The working lunch was designed to provide an informal opportunity for PCPs to 
come together with the research team and talk about the tool. To start, a brief presentation 
on ARVC caused by the TMEM43 mutation was given by the author. Topics covered in 
this brief presentation included disease symptomology and presentation, rates of SCD 
seen in this type of ARVC and treatment options. Participants were also informed about 
the referral process for suspected high-risk individuals. After the presentation, PCPs were 
asked for their initial thoughts about ARVC and their familiarity with it in their practice. 
They were asked to review the tool with the team and have an open-ended discussion 
about the information found in the tool, and the predicted ease and applicability of the 
tool in family practice. It was hoped that through this open-ended discussion, information 
obtained would help modify the tool to better reflect the needs expressed by PCPs 
regarding what they would need to know in order to determine if an individual was at 
high risk for having ARVC.  
Team members present included Dr. Kathy Hodgkinson, Dr. Holly Etchegary, and 
Lauren Rickert. All team members helped facilitate the discussion with PCPs and all took 
detailed field notes for further interpretation and thematic analysis. Feedback was also 
sought through a short, eight question Likert survey with three open-ended questions for 
physicians to provide feedback on the tool, specifically ways to improve the tool and any 
important information that PCPs felt was missing. These surveys were answered 
anonymously and returned to the team by PCPs on completion (see Appendix E). Likert 
scale questions included asking PCPs if “the tool seemed easy to use”; “the layout was 
easy to follow”; and “overall, this tool will help me correctly refer high-risk cardiac 




ranged from 1-Strongly Disagree to 5-Strongly Agree. In addition, the open-ended 
questions asked more general questions, such as “Was there important information 
missing? Please explain”; and “Please identify one way this tool could be improved.” 
Qualitative data collected through open-ended items were analyzed using 
descriptive thematic analysis to help highlight and prioritize areas on the first draft of the 
tool that needed modification. Two team members (Dr. Holly Etchegary and Lauren 
Rickert) read PCPs’ comments and team members’ field notes to identify common 
themes using the method of constant comparison (Pope et al., 2000; & Sandelowski, 
2000). Here, notes and open comments on the survey were read and re-read to identify 
emerging similarities or differences in PCP comments about the tool. Descriptive 
statistics (means, counts, percentages) were determined to help describe PCPs opinions 
on the draft tool. 
Stage 3 – Revising the Initial Draft of the Tool 
The team met after the working lunch following the return of all physical and 
electronic copies of the survey, to discuss the results and to incorporate them into an 
updated tool. The verbal feedback and results from the surveys were analyzed to 
determine what PCPs identified as gaps in the tool and information that was needed to 
make the tool more applicable and/or easy to use in practice. At this time, the team also 
reflected on the existing clinical and research database containing information on all the 
families in the province affected by ARVC due to TMEM43 p.S358L. Previous research 
using the database (Hodgkinson et al., 2013) had shown that symptoms and clinical tests, 
with the exception of the Holter Monitor, were poor discriminators of those with ARVC 




PCPs would likely have (a) had no clinical testing done themselves, likely being non-
discriminatory anyway, and (b) would not know what clinical testing others in their 
family would have had. However, family pedigrees might hold more information than 
was currently captured in the database. Therefore, it was decided that to better inform the 
tool, more information from family pedigrees would be extracted, and added to the 
database.  
Acknowledging the areas identified by PCPs as needing clarity and modifications, 
an updated tool was drafted (see Appendix F). It provided background information on 
ARVC caused by the TMEM43 p.S358L mutation, as well as clinical data that might 
indicate a problem. These risk-factors were characterized as: 
1. Symptomology (syncope/pre-syncope) 
2. Heart rhythm data (PVC’s) and presence of non-sustained VT. Information for 
items 1 and 2 came from the natural history paper (Hodgkinson et al., 2013) and 
the existing dataset 
3. Number of relatives who have documented evidence of SCD or an obvious 
cardiac problem (an ICD or cardiac transplant) 
4. Recommendations for referral to the Cardiac Genetics Clinic in St. John’s, NL. 
 Using the pedigrees to inform the tool. 
 As persons attending a PCP office would not necessarily have had any cardiac 




papers describing ARVC due to TMEM43 p.S358Lthat the first symptom may be death) it 
was felt that the most compelling data may come from the FH.  
The TMEM43 p.S358L dataset is not linked directly to a pedigree, so there was no 
ability to determine from the dataset itself the level of FH each affected person had at the 
time they presented to the medical care system. In other words, how many relatives had a 
significant cardiac event, and how close were those relatives to the patient. These would 
be questions which a PCP could ask a patient, and which they would likely know. Family 
pedigrees would need to be closely examined to determine this.  
 Family Pedigrees. 
Geneticists can analyze a large family tree and, with experience, know what this is 
suggesting in terms of the FH of a condition. PCPs are expected to be able to complete a 
family tree, as it is a core competency. However, family trees in general practice tend to 
focus on the nuclear family, such as parents and siblings, and are considered extensive if 
they capture three generations. The pedigrees used to inform the database include over 
1000 persons, comprising of greater than 10 generations. Therefore, the research team 
could access far more information than a PCP would ever typically have or be able to 
collect during a routine appointment. Thus, we wanted to assess the pedigrees to quantify 
how many obviously affected relatives a person who is now known to be affected had in 
their family tree at the time they presented to the medical professional (e.g., those in their 
family who had died suddenly, those post-transplant, or those with an ICD).  
We hoped to quantify the level of information that would be useful based upon the 
degree of relatedness. For example, many PCPs might presume that the only person in 




with ARVC can have extreme variability in expression of the mutation, as well as 
acknowledging that each child of an affected individual has a 50% risk of inheriting the 
mutation, examination of first degree relatives who died before age 50 due to SCD is not 
enough. For example, it is known that this form of ARVC is less severe in females. While 
the female may carry the mutation and pass it to her offspring, she may never know she is 
a carrier for the disease due to the less obvious physical expression of the disease (if we 
do clinical cardiac tests, the disease is seen in females, but often not to an extent that 
brings them to a doctor). Therefore, her male offspring may present to the physician, and 
if only SCD in first degree relatives is noted, the male offspring’s risk could be missed 
since his first-degree relatives may be clinically well. However, if we look back to the 
patient’s second or third-degree relatives, we may find that the patient’s maternal 
grandfather died at 45 from SCD and his maternal great-grandfather at 39.  
Two team members (Dr. Kathy Hodgkinson and student Lauren Rickert) met 
weekly for a period of three months to discuss and extract the family pedigree data. The 
pedigrees were well established and documented. As mentioned, a variable which would 
denote the number of obviously affected relatives within the data set was necessary. In 
order to create this variable, all affected individuals were determined from the dataset (n= 
409). At the point of ascertainment of the affected person (which was the date they 
became known to the medical team), the pedigree was assessed for relatives to this person 
with obvious disease (SCD, ICD placement, or cardiac transplant), who would have had 
this diagnosis prior to the date the ascertained person was first seen. Typically, people 
tend to know of relatives with severe disease, while they may not necessarily know of 




search was to document the number of relatives the affected person could potentially have 
known about just prior to the date of their ascertainment by the health care system.  
Using this methodology, all first-, second-, and third-degree relatives with obvious 
disease were counted, and added to the dataset as a variable associated with that specific 
affected individual. The purpose of this was to explore if an easy question, such as “do 
you have any relatives who have had an early death, a heart transplant, or the 
implantation of a device designed to pace and shock the heart back to a normal rhythm?” 
would be useful as a clear red flag. To do this, it was necessary to know how many at risk 
individuals had, and what degree of relation, a first-, second-, or third-degree relative. 
This was a question we had not previously asked of the dataset in this context, and thus, 
was not currently captured in the existing dataset.  
 Clinical test results. 
The on-going research has determined which clinical features are common in 
persons with ARVC caused by TMEM43 p.S358L. However, none are useful 
diagnostically themselves, with the exception of ectopy (number of PVCs, or VTs) on the 
Holter Monitor. Poor R-Wave Progression (PRWP) or a 12-lead ECG is a clinical test 
that is not used for diagnosis, but if paired in conjunction with a FH, would be important. 
Acknowledging this, we felt we could use the clinical features, in conjunction with FH to 
help PCPs. Therefore, these were taken into account in the final version of the tool.   
Stage 4 – Surveying a Larger Sample of PCPs and Family Medicine Residents: 
Revised Tool 
 Relevant PCPs, Family Medicine Residents, and professional organizations were 




the project as well as an updated draft of the tool, with a request to review the contents 
and provide feedback via an on-line survey. Careful consideration was given to include 
practicing PCPs in NL, Family Medicine Residents from Memorial University of NL who 
would soon be practicing PCPs, as well as their governing professional body, the 
Newfoundland and Labrador Medical Association (NLMA). 
Through a working collaboration with the Health Sciences Information and Media 
Services (HSIMS), Faculty of Medicine, Memorial University of Newfoundland, the tool 
finalized in Stage 3 was adapted to an electronic PDF, with the same information found in 
Appendix F. Additionally, an online version of the survey was created utilizing the 
Survey Planet platform (https://surveyplanet.com) and a link to the survey was integrated 
into the PDF copy of the tool. 
The updated version of the tool was sent to all Family Medicine Residents within 
Memorial University of Newfoundland through the list serve for the Faculty of Medicine 
in March 2018. Specifically, Family Medicine Residents were sent an e-mail (see 
Appendix H) with a description of the project, as well as a PDF attachment of the tool, 
and a link to the online survey (https://s.surveyplanet.com/Bym_glXtG) containing nine 
Likert-scale questions, two qualitative questions and five demographic questions (see 
Appendix G). An e-mail reminder was sent to Family Medicine Residents approximately 
one month after the initial e-mail was distributed. Data were collected and analyzed up to 
July 1, 2018.  
Additionally, the NLMA provided an advertisement in their newsletter, inviting 
PCPs to review and provide feedback through an online survey (see Appendix I). This 




Furthermore, all PCPs practising within NL were sent an e-mail with the PDF 
attachment and online survey link through the list serve of the NL College of Family 
Physicians (see Appendix J). This e-mail was distributed in May 2018. The physicians 
who attended the original working lunch were also personally contacted and advised of 
the revised tool. They were provided the PDF copy of the tool, as well as a link to the 
survey (see Appendix K). All data on the feedback of the tool was only used if it was 
received prior to July 1, 2018. No financial incentives were used to help in recruitment. 
The literature suggests a mean response rate of 56% for paper-based surveys, and 
33% for online surveys (Nulty, 2008). Acknowledging there are about 710 PCPs in the 
province of NL (Ms. Debbie Rideout, personal communication, June 2018), and 70 
Family Medicine Residents (Dr. Susan Avery, personal communication, September 
2016), this gives an anticipated response rate of the survey to be about 117 PCPs and 
Family Medicine Residents. However, it is important to acknowledge here that 
recruitment of PCPs in research studies is a known obstacle faced by researchers. They 
are a documented difficult group to recruit, and with limited empirical data on the 
effectiveness of various recruitment strategies to help guide the research design, actual 
response rates will not be reflective of the rate anticipated in the literature (Boulet et al., 
2013).  
Qualitative description was used to analyze responses to two open-ended 
qualitative survey items. Comments were independently read by the author, then re-read 
by another team member (Dr. Holly Etchegary) to identify emerging categories and 




quantitative data to explore any relationships among survey demographic items and items 
assessing the tool. 
Summary 
Based on a working lunch held with PCPs, a number of areas of concern were 
identified with the original draft of the educational tool. Utilizing their feedback, and pre-
existing FH data on families with this type of ARVC, a modified tool was created and 
distributed via an on-line resource, as well as through e-mail for PCPs and Family 
Medicine Residents to view and provide further feedback on. The results of the feedback 




















 In total, 10 physicians were contacted via e-mail or in person and asked to attend 
the working lunch.  
Participants  
The draft tool (see Appendix C) was presented to PCPs during a working lunch in 
May 2016 at the Faculty of Medicine, Memorial University, Health Sciences Centre. 
Feedback on the tool was provided by a total of five PCPs (four male). Three PCPs 
attended the working lunch (two males, one female), and two PCPs provided their 
feedback electronically (two male). All participants were practicing in an academic 
setting; none were community physicians.  
 Analysis. 
 Quantitative and qualitative data recorded through the working lunch and an eight 
item, five-point Likert scale survey with open-ended questions provided the team with the 
feedback necessary to revise the first draft of the tool.   
 Quantitative data. 
Descriptive statistics (means, counts, percentages) are provided to describe PCPs’ 
opinion on the draft tool. Overall, the results from the survey from the working lunch 
revealed that the tool needed substantial revision to increase the ease of readability, as 






Table 1: Response distribution from Focus Group Survey, May 2016 [n (%)] 
Question/Mean Response Strongly 
Disagree 
Disagree Undecided Agree Strongly 
Agree 
The tool seems easy to use 0 3 (60%) 1 (20%) 1 (20%) 0 
The purpose of the tool was clearly stated 0 0 1 (20%) 1 (20%) 3 (60%) 
The instructions were clear* 0 3 (60%) 0 1 (20%) 0 
The layout was easy to follow 0 4 (80%) 1 (20%) 0 0 
The information was easy to understand 0 0 1 (20%) 4 (80%) 0 
I feel this tool has increased my knowledge 
about ARVC in NL 
0 0 1 (20%) 2 (40%) 2 (40%) 
Overall, this tool would be helpful to me in 
my practice 
0 1 (20%) 1 (20%) 2 (40%) 1 (20%) 
Overall, this tool will help me correctly 
refer high-risk cardiac families to the 
genetics cardiology service 
0 2 (40%) 1 (20%) 1 (20%) 1 (20%) 
*indicates that a response was missing from this question 
 60% of PCPs indicated the tool did not seem easy to use; 60% did not find the 
instructions clear nor the layout easy to follow. Forty percent did not agree the tool would 
help refer high-risk cardiac patients to the cardiac genetics clinic. Alternatively, however, 
60% of PCPs felt that they were either undecided, agreed, or strongly agreed that the tool 
would help refer high risk cardiac patients appropriately. Most participants agreed the 
purpose of the tool was clearly stated, with 80% agreeing that the information itself was 
easy to understand, and 80% of PCPs agreed or strongly agreed that the tool helped 
increase their knowledge on ARVC. Overall, 60% agreed or strongly agreed (40% and 
20%, respectively) that the tool would be helpful in their practice.  
 Qualitative data. 
 Two qualitative questions were asked in the survey for additional feedback: “Was 




tool can be improved.” Qualitative data collected through open-ended items were 
analyzed using descriptive thematic analysis to help highlight and prioritize areas on the 
first draft of the tool that needed modification. Two team members (Dr. Holly Etchegary 
and Lauren Rickert) read PCPs’ comments and team members’ field notes to identify 
common themes using the method of constant comparison (Pope et al., 2000; & 
Sandelowski, 2000). Here, notes and open comments on the survey were read and re-read 
to identify emerging similarities or differences in PCP comments about the tool. Overall, 
two key themes were identified. These were (a) the ease of using the tool in practice, and 
(b) the need for clear descriptions of symptom presentation.  
1) Ease of utilizing the tool in practice.  
 PCPs noted the need to shorten the tool, pointing to the importance of short, 
concise messages that would facilitate its use in practice. One noted the tool needed to 
present practical information first. 
 PCPs also asked for clarity regarding what they should do when faced with an 
individual or family who are at risk for carrying the TMEM43 p.S358L mutation. 
Notably, they wanted clear instructions on how to refer families properly to appropriate 
health care services including genetic screening or the cardiac clinic. They noted a need 
for clear decision trees for who is appropriate to refer and advice on how to triage patients 
to prevent unnecessary referral.   
More clear decision trees for who is appropriate for referral, probably including 
Holter results. 





The message might be that anyone with pre-syncope or palpitations would be 
referred. The (genetics) clinic would not be happy. 
This sort of practical information was thought to make the tool easier to use in 
practice.  
 2) More precise descriptions of symptom presentation.  
PCPs noted that clear descriptions of symptom presentation would enable them to screen 
at risk individuals appropriately. As suggested by one PCP, the tool could provide advice 
on whether findings on ECG, CXR, or echo are useful in triaging patients.  
Advice on whether findings on ECG, CXR, or echo are useful in triaging the 
positive likelihood of ARVC would also be useful in triaging Pts. 
Notably, PCPs indicated that recognizing the symptoms and clinical presentation of 
individuals at risk would be easier if quantitative data reflecting early warning signs of 
the disease could be incorporated into the tool.  
Family Pedigree Data 
Past work by the team had clearly shown that no signs and symptoms of the 
disease were useful in discerning those with and without the disease, within known 
families. Therefore, it was clear that these would be even less useful in a general 
population sample (Hodgkinson, 2013). Even symptoms which would be suspected, for 
example palpitations and syncope, had no diagnostic utility when assessed within the 
larger ARVC families (using those found to not have the TMEM 43 p. S358L mutation as 
controls). In terms of clinical tests, only the Holter Monitor was diagnostically useful 




The 27 known families were assessed for the number of first-, second-, or third- 
degree relatives (with SCD) greater than or equal to 50 years of age) of affected 
individuals (n=409). The number of relatives in the family who would have clearly shown 
evidence of the disease prior to their death were then pulled from the data; this included 
(a) SCD, (b) surgery for ICD placement, and (c) heart transplant. Of these 409, 160 were 
diagnosed following SCD (i.e., unrecognized as being at risk prior to their final 
symptom). Of these 160, 56%, 39% and 31% had at least one first-, one second- and one 
third- degree relative presenting with an SCD (less than or equal to 50 years of age) 
respectively, with 19% having no known affected relatives (Figure 1). 
 
Figure 1: Percentage of Relatives with SCD/ICD/Heart Transplant among 
Individuals with SCD 







No known relatives with SCD





This was the first time the data set and family histories had been assessed in this 
manner. It permitted for a clear demonstration of the usefulness of accurate, multi-
generational FH in this disease. 
 As seen in Figure 1, 56% of people who had a SCD event had at least one first-
degree relative with a history of SCD, 39% of people who had a SCD event, ICD 
placement, or a heart transplant, had at least one second-degree relative with a history of 
SCD, 31% of people who had a SCD event, ICD placement, or a heart transplant, had at 
least one third-degree relative with a history of SCD, and finally, 19% of people who had 
a SCD event, ICD placement, or a heart transplant, had no known relatives with any SCD 
events. It was evident from these findings that some individuals had a first-, second-, and 
third-degree relatives who had a SCD event, ICD placement, or a heart transplant.  
 The qualitative feedback, as well as the information obtained from the Family 
Pedigree data were used to inform the next iteration of the tool. For example, additional 
information was added to the tool to prompt providers to discuss an extended family 
history with patients (see Appendix F for revised tool). 
Online Survey 
 Participants 
43/780 online surveys were completed by this group. This represents roughly 
5.5% of Family Medicine Residents and PCPs completing the online survey. While 
upwards of 780 Family Medicine Residents and PCPs would have received some 
notification either through e-mail or through the NLMA website and advertisement, there 
is no way to determine exactly how many received the e-mail, opened it, or saw the ad. 




Participants were almost equally male (n=22, 52.4%) and female (n=20, 47.6 %), with 
59.5% being between the ages of 45 to 64 (n=25). 32.2% of respondents were between 
the ages of 24-44 (n=14), with 9.1% were 65 or older (n= four). Participants were most 
likely to indicate having their practice in the community (n=26, 61.9%). Other settings for 
practice included hospital (n=ten, 23.8%), academic, and other (n=three each, 6.8%) 
(Figure 2). 27 participants, or 61.4%, were most likely to be practicing within the Eastern 
Regional Health Authority, with eight participants, or 19.5% practicing within the Central 
Regional Health Authority, and a smaller number of representatives from the Western 
Regional Health Authority (n=four) and two participants from the Labrador-Grenfell 
Regional Health Authority (9.8% and 4.9%, respectively, Figure 3). 
Participants reported to have been practicing an average of 13.4 years, with a 
range of 1 to 20 years. Responses were combined for both Family Medicine Residents 
and practicing PCPs as response rates were low and answers did not vary greatly between 









Figure 3: Location of Physician Practice 
Community Hospital Academic Other





It is important to note, however, that some questions were not answered by all 
participants. Questions two through eight have responses from 42 participants, and 
question one had responses from 43 participants. The total percentage of missing data was 
2.3% for question one, and 4.5% for questions two through eight. No imputation was 
performed for this small amount of missing data as they are assumed to be missing at 
random. The percentages are reflective of the total number of responses, with missing 
data excluded from the calculations.  
Quantitative Data. 
Table 2 and Figure 4 display descriptive statistics for items on the online survey  
 
 
Table 2: Mean Response from Online Survey 
Question Mean Response (SD) 
The tool seems easy to use 4.21 (.742) 
The purpose of the tool was clearly stated 4.36 (.791) 
The instructions were clear 4.29 (.742) 
The layout was easy to follow 4.07 (.921) 
The information was easy to understand 4.36 (.727) 
I feel this tool has increased my knowledge 
about ARVC in NL 
4.38 (.731) 
Overall, this tool would be helpful to me in 
my practice 
4.24 (.576) 
Overall, this tool will help me correctly refer 
















0 5 10 15 20 25 30
The tool seems easy to use
The purpose of the tool was clearly
stated
The instructions were clear
The layout was easy to follow
The information was easy to
understand
I feel this tool has increased my
knowledge about ARVC in NL
Overall, this tool would be helpful to
me in my practice
Overall, this tool will help me correctly
refer high-risk cardiac families to
genetics cardiology services




Overall, the survey results indicated a great improvement of the tool from the 
initial draft. Almost all participants (93.1%) agreed or strongly agreed that the tool 
seemed easy to use, and that the purpose of the tool was clearly stated (92.8%). Similarly, 
95.2% of participants felt the instructions on the revised tool were clear, and 83.3% 
agreed or strongly agreed that the layout was easy to follow. Almost all participants 
agreed or strongly agreed (97.7%) that the information was easy to understand, with 
90.5% identifying that the tool had increased their knowledge about ARVC in NL. 
Furthermore, and perhaps one of the most important features of the tool, almost all 
participants (92.9%) reported that the tool would be helpful in their practice. Finally, 
95.2% of participants reported that they felt the tool would help them correctly refer 
potentially high-risk cardiac families to the genetics cardiology services.  
Statistical Analysis.  
A correlational analysis was undertaken to explore any relationships among 
survey demographic items and items assessing the tool. Table 3 presents the results of the 












Table 3: Correlational Analysis of Survey Items and Demographic Items 
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As shown in Table 3, there was no significant correlation between participants’ 
demographic information and their responses to any of the survey items. As a result, 
further analyses were not undertaken.  
 While scale validation was not the intent of this study, nor possible with the 
study’s small sample, an exploratory reliability analysis revealed the survey items did 
appear reliable (Cronbach’s α= .887). Thus, the items used to measure attitude towards 
the educational tool developed in this study do appear a useful place to start in research 
with larger samples. 
Qualitative Data. 
Qualitative description was used to analyze responses to two open-ended survey 
items. Comments were independently read by the author, then re-read by another team 
member to identify emerging categories and themes within the narrative feedback. Very 
minor differences in themes were resolved through discussion and review of the data. 
Thematic analysis was shared with the full research team to derive the final, following 
themes. Appendix L contains the full set of all qualitative responses from participants.  
The main themes that arose during analysis related to areas for tool improvement 
and ease of utilizing the tool in practice.  
1. Suggested improvements to the tool:  
Participants made several suggestions on areas for improvements in the tool, or 
similar tools, in the future. Several participants expressed a need for the Genetics Referral 
Form to be connected, or accessible, from the tool itself: 
A referral form is referred to CH1632-where to find it? Participant (P) 35, Male, 




Provincial Medical Genetics Referral form, used for referrals to the Genetics 
program throughout the province of NL) 
 
Put the form required for a genetics referral at the end of the tool in a format 
which can be printed. P. 25, Female, 55-64, Community setting, Eastern Health 
 
Other suggestions pointed to the accessibility of the information and the ease with 
which it is located: 
Flow chart visual for office would help. P.36, Female, 45-54, Community setting, 
Central Health 
 
A schematic or something more visual/ flow sheet etc. would be helpful... P.16, 
Female, 45-54, Academic setting, Eastern Health 
 
Add it to the Med Access list of templates-perhaps ensure that the referral form is 
also available in the Med Access platform. P.14, Male, 45-54, Community setting, 
Eastern Health 
 
A simple highlight box somewhere on the document could helpful as a quick 
reference to those 6 clinical pearls (red flags/clinical tests. P.12, Male, 24-34, 
Community setting, Eastern Health  
 
2. Ease of utilizing the tool in practice:  
Participants identified some features of the tool which could be improved upon in 
order to increase the ease of utilizing the tool in practice: 
How urgent should the referral be? How long will my patients be expected to wait 
to see cardiology or genetics? P.41, Male, 35-44, Hospital setting, Eastern Health 
 
Very busy form-probably not every detail is necessary. P.35, Male, 45-54, 
Hospital setting, Eastern Health 
 
One-page screening form with checkboxes. P.26, Male, 55-64, Community 
setting, Eastern Health 
 






...would be doing a “patient version” that could be given to patients at the same 
time we are using ours as clinicians to get the process started. P.4, Male, 24-34, 
Community setting, Central Health 
 
One participant highlighted that narrowing down those patients who are most in 
need of a referral was critical: 
In Newfoundland, there are many cases of early ischemic heart disease likely 
linked to diabetes, obesity, hypertension and genetics. So, every relative of one of 
these patients should be referred to genetics? I feel that would overwhelm the 
system. P.23, Female, 45-54, Community setting, Eastern Health 
 
 While the quantitative results indicated largely positive impressions of the tool, 
the qualitative data highlight nuanced areas of improvement for an easily accessible, easy 
to understand tool which will help identify individuals and families potentially affected 
with ARVC caused by the TMEM43 mutation. One very positive response should be 
identified as to the success of the tool, and potential for similar tools in the future for 
diseases prevalent within the province: 
There is nothing missing! I have had several patients with ARVC in my practice 
over the years and this teaching tool is an absolute gem. It is concise, very well 
organized, and flows extremely well. All of the information is there. It's short and 
very sweet. Well done and please keep up the good work, as it is very well 













ARVC is a Mendelian, autosomal dominant disorder with at least 12 genes 
identified as clinically associated with the condition (“ARVC-Genetics Home Reference- 
NIH”, 2019). A specific type of ARVC caused by the p. S358L mutation in TMEM43 is of 
focus in this thesis and is of particular importance to the population of NL, Canada. One 
manifestation of this disease, which is often the first symptom presentation, is SCD, 
particularly in males, at a very young age. However, with appropriate medical 
intervention, most successfully with implantation of ICDs, mortality is significantly 
reduced (Hodgkinson et al., 2006; Hodgkinson et al., 2016). Mortality can only be 
reduced through proper diagnosis of the disease. Healthcare professionals must be able to 
identify individuals and families at risk, and offer appropriate medical intervention, prior 
to an unexpected death. For the population of focus in this thesis, those within the 
TMEM43 population, once an individual has been shown to have the disease and/or the 
mutation, the individual’s at risk family members can be tested and treated, if necessary, 
before a SCD event. However, this assumes that the initial individual with the mutation is 
identified before a serious and potentially fatal cardiac event. Thus, the purpose of this 
thesis is to facilitate the identification of the initial individual, and subsequently, at risk 
family members, prior to a serious event.  
 A short, paper-based draft tool was given to a small group of PCPs. Considering 
the feedback obtained, work needed to be included in the revised version of the tool 
including ease of tool use and clarity of instructions. Feedback obtained also indicated a 
need for clinical test results, if available, and concerns on how to prevent unnecessary 




high risk patients appropriately. A second version of the tool was created which utilized 
information from a large, pre-existing data set on all 27 known ARVC families within the 
province of NL. This revised tool was distributed to a larger group of PCPs and Family 
Medicine Residents. A survey was also distributed with the tool seeking feedback on the 
revised version. 43 surveys were completed. Overall, responses from the survey were 
positive, with suggestions provided on how to further improve the tool.  
 Genetic and genomic medicine has increasingly become integrated into primary 
care (Melo et al., 2015). This integration can allow for more precise, patient-centered 
care; however, it has not come without its resistance (Carroll et al., 2016b). Evidence 
indicates that PCPs recognize the importance of integrating genetics and genomics into 
their family practice, but a number of concerns have been identified, such as lack of 
confidence in referring and counselling patients regarding genetic conditions, and a 
general lack of knowledge, skills and experience in genetics and genomics medicine. 
(Harding et al., 2019; & Mikat-Stevens et al., 2015).  
One important core competency of PCPs is establishing a FH (Korf et al., 2014; & 
Mikat-Stevens et al., 2015). More importantly, multi-generational family histories clearly 
highlight inherited diseases when accurately obtained (Waddell-Smith et al., 2016). The 
importance of obtaining accurate family histories is indicated in other literature, further 
highlighting the significance. Forsti et al. (2016) reported that informative family 
pedigrees were essential in determining the genes and variants associated with 
Mendelian-type cancers. In Sweden, Hemminki et al. (2018) utilized hospital records of 
the Multigenerational Register to assess if there was a genetic link to urinary tract stone 




genetic link for this condition. Sundquist et al. (2015) reported that a FH presence of 
venous thromboembolism (VTE) is a predictor of VTE reoccurrence; however, they only 
examined VTE history in first-degree relatives.  
Accurate family histories allow for the recognition of persons who were not 
recently thought to have a specific disease or condition, but in fact do. This can be caused 
by variable expression of the condition, as well as reduced penetrance. Also, accurate 
family histories help clarify those who thought they had a certain disease or condition, but 
actually do not. Clarification in these situations further demonstrates the importance of 
obtaining accurate family histories, an invaluable resource to PCPs as well as other 
specialized practitioners (Dunn et al., 2013).  
While the clinical importance of obtaining multi-generation family histories has 
long been noted (e.g., Carroll et al, 2016b; Dunn et al., 2013; Waddell-Smith et al., 2016; 
& Wilson et al., 2016), it is particularly important for a condition where the first symptom 
is often death. Obtaining multi-generational family histories to identify those most at risk 
for inheriting this lethal type of ARVC could potentially prevent SCD. Importantly, 
Kauferstein et al. (2017) did note that together with clinical testing data, FH can be an 
important diagnostic tool, especially in diseases which have variable expression and 
reduced penetrance. Ranthe et al. (2012) also reported findings from their study, which 
advised that FH of premature cardiovascular death is an accurate predictor of risk for 
cardiovascular disease (p. 821). Additionally,  Hookana et al. (2012) reported that FH is a 
strong predictor of SCD caused by ischemic SCD, though investigators only examined 
first degree relatives. However, in a review of the relevant literature which examined 




investigated participants’ first-degree relatives when examining cardiac diseases 
(Chinushi et al., 2012; Dekker et al., 2006; Emery et al., 2018; & Hookana, et al., 2012). 
Other research provides no clear distinction on what degree of FH was investigated (Petri 
et al., 2014). However, there is some evidence of the inclusion of second-degree relatives, 
and to a lesser extent, third-degree relatives, in the literature (Kauferstein et al., 2017; 
Ranthe et al., 2012; & Waddel-Smith et al., 2016). While noting the concerns raised by 
PCPs about obtaining family histories, and genetics and genomics medicine, this study 
has further reinforced the need to obtain accurate multi-generational family histories. As 
discussed above, other authors (Waddell-Smith et al., 2016; Wilson et al. 2016; & Wood 
et al., 2013), have all identified issues with PCPs accurately taking FH data from patients, 
whether it is from inconsistencies in obtaining the data, or due to PCPs perceptions of 
their roles in obtaining family histories.  
As identified by Waddell-Smith et al. (2016), detailed family histories are not 
often obtained by inpatient general medicine and cardiology staff, and when they are 
recorded, it is often done incorrectly with misleading information. Wood et al. (2013) also 
reported inconsistencies with PCPs in their FH taking in practice. Finally, as 
demonstrated by Wilson et. al. (2016), PCPs did report high, positive intentions for 
completing patients’ family histories; however, it was identified that a proportion of their 
PCP respondents noted that FH taking was not something they felt was expected of them 
or something in which they felt confident in doing. Given the concerns raised by PCPs 
regarding the integration of genetics and genomics into primary care, as well as 
acknowledging the importance of accurately obtaining multi-generational family 




Educational tools are an effective, cost efficient method of highlighting important 
information for PCPs (Carroll et al., 2011; Genova et al., 2014; & Grimshaw et al., 2014).  
The implications of this are suggested in the literature, including more accessible guides 
to management and referral options for higher risk patients (Wood et al., 2013), point-of-
care tools which highlight competencies and content knowledge (Wilson et al., 2016), and 
knowledge translation efforts like those seen by Carroll et al. (2016a). In that study, a 
GenetiKit was created, which consisted of a knowledge translation package of a case-
based interactive educational workshop, portfolio of primary care-appropriate genetics 
tools, and responsive timely knowledge support service called Gene Messenger. This 
study found that 90% of PCPs who participated wanted to continue to receive Gene 
Messengers, two-page evidence based structured summaries of various gene-disease 
associations or other genetic conditions heard commonly in the media. Continuing 
education efforts for currently practicing PCPs are an effective way to communicate 
genetic information. Increased training in medical school, as well as during residencies, is 
another suggestion on how to bridge the gap between knowledge and practice (Carroll et 
al., 2016b). The unique findings in this thesis clearly highlight the importance of 
obtaining accurate family histories to include at least third-degree relatives. 
The motivation for this work was the desire to enable PCPs to more accurately 
ascertain those potentially at risk of ARVC caused by the p.S358L mutation in TMEM43 
before a catastrophic event, such as SCD. One way to do this, and the method we chose to 
use in this project, would be to develop an educational tool which informs PCPs about 
this type of ARVC. This was accomplished by (a) the creation of a draft tool utilizing past 




input from a small group of PCPs in a focus group, and (c) modification of the tool via 
input from PCPs and PCP residents to obtain a final product. Implementation and 
evaluation of the tool are beyond the scope of this project, and therefore, the purpose was 
to develop an educational tool which could potentially be used to inform PCPs about this 
specific type of ARVC.  
Our findings illustrated several issues and suggest some tentative conclusions. 
Firstly, through consultation with PCPs, we developed a tool for ARVC caused by the p. 
S358L mutation in TMEM43 that was rated as easy to use, having a clear purpose and 
instructions, and containing comprehensible information. PCPs agreed the tool helped 
increase their knowledge about ARVC, would be helpful in practice, and has the potential 
to help physicians correctly identify those at high-risk and needing a referral to the 
genetics program. This study revealed that a short, inexpensive tool could be created that 
PCPs rate highly. Tools similar to the one created for this thesis may help bridge the gap 
between bench-side genomics research and help with the implementation of genetics 
findings into primary care practice (Carroll et al., 2016a; Mikat-Stevens et al., 2015; & 
Scott and Trotter, 2013). Furthermore, this study provides evidence that printed 
educational tools in primary care practice can be created in a cost-effective manner, are 
rated highly by PCPs, and can be effective ways to communicate important health 
information (Genova et al., 2014; Grimshaw et al., 2014; & Williams et al., 2015). As the 
results from the online survey demonstrate, PCPs identified an increase in knowledge and 
a desire to integrate the tool into practice, similar to other studies of genetics educational 




Printed educational materials have had positive impacts on patient care, in both 
genetic and non-genetic patient samples. For example, Shah et al. (2010) reported in their 
trial that the use of printed educational materials had a small to moderate impact on PCPs 
and patient care. This study explored the impact of guidelines established by the Canadian 
Diabetes Association to improve cardiovascular disease screening, prevention, and 
treatment for those with diabetes. Given the relatively low cost and feasibility of printed 
educational materials, it was suggested that these should be considered to improve patient 
care. Watson et al. (2001) also reported similar positive findings in their study on the use 
of printed educational materials for referral decisions for individuals with a FH of breast 
and ovarian cancer. Utilizing laminated summary cards with simple referral guidelines, 
and booklets with more detailed background information and patient leaflets, they found a 
major improvement on general practitioners’ referral decisions. Alternatively, they also 
presented general practitioners with an in-person education session, in combination with 
the printed educational materials, and found it had no additive benefit for referral 
decisions compared to the group who only received the printed educational materials. 
Another study which examined the use of paper-based educational tools on evidence-
based practices (EBPs) found that these tools can be effective in disseminating EBPs to 
health care professionals, particularly if there was pre-existing interest in EBPs with 
supportive attitudes. Using a coloured, two-page reference sheet and a 12-page booklet, 
the authors found that their information package was a well-received tool to disseminate 
information on EBPs. Similar to tool development in this thesis, the authors first 
conducted a pilot study of the information package to garner feedback that informed a 




Finally, a study from Carroll et al. (2011) looked at family physicians and genetic testing 
referrals. The authors implemented an interactive educational workshop, a collection of 
practical primary care clinical genetics tools and a knowledge service called Gene 
Messenger. This multi-faceted intervention significantly improved genetics referral 
decision making specifically pertaining to provincial guidelines regarding hereditary 
breast and ovarian cancer, while also increasing confidence regarding core genetic 
competencies seen in primary care.  
However, here it is important to highlight criticisms or critiques of paper-based 
educational tools. As cited in Zwarenstein et al. (2014), screening of retinopathy, a 
serious eye complication in patients with diabetes, was done through family physician 
referrals. Family physicians typically initiate these referrals. Their interventions of either 
an evidence-based, post-card sized document, or a two-page document highlighting the 
same information, had no impact on physician referral rates for retinal screening rates for 
diabetes patients. A Cochrane systematic review on the use of printed educational 
materials concluded that, when compared to no intervention, printed educational materials 
may have a slight positive impact on process outcomes (the behavior of the healthcare 
professional) but no impact on improving patient outcomes or patient health (Farmer et 
al., 2008). Finally, as reported by Presseau et al. (2016), printed educational materials had 
no impact on family physician prescribing behavior for a medication to treat 
hypertension. 
There are, however, suggestions made in the literature to increase knowledge 
uptake of the important information often found within these printed educational 




workshop with a family physician and a genetic counsellor, and as reported above, 
improved family physician referrals for patients at risk for hereditary breast and ovarian 
cancer (Carroll et al., 2011). Pimenta et al., (2014) also similarly reported on the success 
of a multi-faceted approach to knowledge translation. Here, one small group discussion of 
routine practices for hypertensive patients, one outreach visit by cardiologists to family 
physician offices, and three e-mail reminders on risk stratification and measures of high-
risk patients were compared to quality of hypertensive patient treatment obtained through 
patient interviews and chart reviews. The comparison group of physicians received only 
the paper-based educational tools. The group of physicians who were in the multi-faceted 
intervention improved the treatment of the hypertensive patients. Though there was some 
improvement seen in the paper-based only educational tools, improvement in patient 
treatment did not reach the same level as that seen in the multi-faceted group. Other 
evidence indicates that PCPs’ perceived ease of use of the educational material, perceived 
usefulness of the material, and attitude towards the material need to be increased in order 
to increase uptake of the information. Working with PCPs in establishing ease of use and 
usefulness will positively improve attitude towards the material, and thus increase uptake 
(Grudniewicz et al., 2015).  
In this study, it is encouraging that PCPs qualitatively rated the tool as easy to use 
and agreed it would be useful in practice. It is important here, as well, to reference the 
data from the online survey. For this tool, or similar tools, to be successful in their 
implementation, information needs to be easily accessible to PCPs, including referrals to 
appropriate specialized departments, which may include the proper referral forms or 




noted flow charts or other visuals would be beneficial. Further information on how to 
grade the urgency of the referral and anticipated wait times based on that urgency would 
also help facilitate the uptake of this or similar tools. If possible, summation of 
information to one page may also increase uptake and use. Also, it is important to 
consider how to streamline referrals such that the system is not more overwhelmed than it 
already is, so that only the most appropriate persons are be provided the most appropriate 
referral. For the disease of focus in this thesis, accurate multi-generational FH data would 
perhaps help facilitate this process and narrow down the number of individuals who are 
referred to the Cardiac Genetics Clinic. Obtaining accurate FH data would also help PCPs 
narrow down questions asked to patients regarding possible familial genetic conditions, 
facilitating more efficient medical care (Dunn et al, 2013).  
Acknowledging this, further efforts could include interactive workshops, or 
educational sessions, at the PCP level, as well as with Family Medicine Residents. 
Furthermore, using the tool as a template, other diseases could be highlighted to 
determine their applicability in practice. Ultimately, to measure the success of this 
specific tool, implementation of the tool into practice and the success of preventing SCD 
in undiagnosed individuals with ARVC caused by the p. S358L mutation in TMEM43 
would need to be measured over a period of time. This is outside the scope of this thesis 
but represents an important area for future research.  
Secondly, we have demonstrated that family pedigrees are vitally important. 
Family pedigrees were analyzed utilizing a pre-existing data set that contains all 
individuals born with an a priori 50% risk of inheriting ARVC caused by the p. S358L 




determine the natural history and clinical course of the disease (Hodgkinson et al., 2013). 
The dataset, and analysis presented in the Hodgkinson et al. (2013) study, demonstrated 
that there were no clinical tests, symptoms, or signs of the disease that could be used in 
diagnosis. This limits the ability for the data set to be used in predicting the disease in an 
undiagnosed individual or determining risk of other family member. There was a gap, 
therefore, in the useful information found within a patient’s FH and the dataset and 
applying that data in determining risk in an undiagnosed individual and their family 
members. This limits the confirmed diagnosis of the disease to a genetic test, which are 
expensive and should be limited to those most likely to have the disease. 
While genetic counsellors and geneticists can read and understand an individual’s 
FH, PCPs often do not have access to this information, certainly not to the depth that 
detailed, multi-generational family histories provide. As previously discussed, PCPs also 
may have limitations on their abilities to read and interpret multi-generational family 
histories. The gap between the information found within family histories, and applying 
that information to help screen at risk individuals and family members could be narrowed 
by providing PCPs with easy to understand and use FH data, assessed through the FH 
data set, which explained the risk a specific individual would have for inheriting the 
mutation. Knowing that people often are aware of early SCD or major surgeries, such as 
heart transplants within their family, we created a variable, which was integrated into the 
tool and given to PCPs, which would help PCPs more easily determine an individual’s 
risk for inheriting the disease. This variable, which clearly establishes the number of first-
, second- and third-degree relatives who were carriers for the mutation, is clear, simple, 




PCPs, to help determine an individual’s risk of inheriting this mutation. Doing this work, 
and creating the variable, allowed us to see the importance of family history of these 
events in determining risk. Giving PCPs this data can help them determine those most in 
need of a referral to appropriate genetics and cardiology services, limiting unnecessary 
referrals. As this tool is provided as a guideline only, it is important to consider that 
unnecessary referrals to cardiology genetic services may still occur. Used appropriately, 
and with the referring physician using their own clinical judgment on patients’ presenting 
symptoms, and FH, it is hoped that unnecessary referrals will be limited. More prompt 
referrals by PCPs to genetics and cardiology services, therefore, would allow the 
individual quicker access to diagnostic utilities, with the potential to prevent SCD seen 
with this disease, in both the individual and within potential at risk family members.  
Analysis of the data set revealed that family pedigree data is an important red flag 
in determining an individual’s risk for having ARVC caused by a mutation in TMEM43. 
Clinically, this finding is notable as FH data can be used to help determine an 
undiagnosed individual’s risk of SCD caused by the disease of focus. The findings of this 
thesis are unique, in that the literature, as noted, indicates obtaining only first-degree 
family histories. It has been shown that obtaining family histories to the third-degree is 
necessary, and essential, when trying to determine an individual’s risk for this specific 
type of ARVC (Chinushi et al., 2012; Dekker et al., 2006; Emery et al., 2018; & Hookana 
et. al., 2012).  
The novel approach seen in this thesis, utilizing a pre-existing data set and FH 
bank, clearly demonstrates the importance of obtaining family histories greater than just 




who have had SCD (i.e., unrecognized as being at risk prior to their final symptom), 56%, 
39% and 31% had at least one first-, one second- and one third- degree relative presenting 
with an SCD (less than or equal to 50 years of age) respectively. Therefore, should an 
individual have presented themselves to their PCP prior to their own SCD, and an 
accurate FH was obtained, it would have been evident that this person had a substantial 
FH of SCD, measurable to the at least the third-degree relative. A PCP, upon seeing this 
very strong evidence in the FH of SCD, would be prompted to refer the individual to 
more appropriate medical services, such as genetics and cardiology, potentially 
preventing the SCD eventually seen in that individual. The tool, in this case, would make 
the decision making more streamlined, ensuring that the highest risk individuals receive 
the adequate and appropriate care. 
Study results represent important clinical findings. Firstly, participants expressed 
positive attitudes and reviews towards the tool and agreed it would be helpful in practice. 
Utilizing it as a template, other diseases common to the province can be highlighted 
quickly, easily, and accessibly by PCPs. This would be advantageous for less common 
diseases, diseases with variable expression, or for PCPs who are from outside the 
province and may not be familiar with common illnesses and syndromes found in 
NL.Packages of tools for common diseases within the province could be provided 
through the NLMA, at the university level, or through each regional health authority.  
Furthermore, acknowledging the unique geography and size of the province, 
similar tools would easily disseminate information to PCPs practicing anywhere in NL. 
Providing similar tools via e-mail or through regular mail permits for easier knowledge 




knowledge transfer. Though again, it is important to highlight that implementation of this 
specific tool is outside the scope of this thesis. Finally, as demonstrated by the work done 
with the family pedigrees and highlighting the risks seen with first-, second-, and third-
degree relatives with a history of SCD, ICD implantation, and heart transplants, clearly 
there is strong evidence to indicate the worth of obtaining multi-generational family 
histories, as has been noted in the literature. Effort should be maintained during medical 
school such that students understand and acknowledge the importance of obtaining family 
histories beyond the first degree relative. Additionally, this could include providing 
medical students with a package of tool which highlight common diseases within the 
province.  
Some limitations of this study should be discussed. Firstly, the initial working 
lunch included a limited number of physicians strictly from an academic setting. The data 
collected during the working lunch do not reflect the perceptions and concerns of 
practitioners outside an academic setting.  However, this was likely off-set by the large 
number of respondents for the online survey who were from community and hospital 
settings. Additionally, physicians are a difficult group to recruit for surveys, and response 
rates for surveys are known to be lower when physicians are asked to complete surveys 
compared to the general population (Brtnikova et. al., 2018). It has been documented that 
physician response rates can be 10% lower than that of the general population (James et 
al., 2011). Similarly, it was noted by Field et. al. (2002), physician response rates ranged 
from 11-39% (p. 597). The literature therefore provides some precedent for the low 
survey response rate seen in this study. Findings, therefore, may not generalize to the 




that may provide a higher response rate is suggested by Brtnikova et al. (2018), who 
reported that a mixed methodology including an online survey, followed by a postal 
survey, may yield a higher response rate. Other incentives, such as monetary incentives as 
well as non-financial incentives have been found to increase physician response rates for 
surveys (Pit et al., 2013; & Young et al, 2015). 
ARVC is a genetic heart condition caused by the p. S358L mutation in TMEM43. 
This specific mutation is prevalent in the province of NL, Canada. This type of ARVC is 
highly lethal in affected individuals, causing SCD in undiagnosed individuals as early as 
19 years old for males and 37 years old for females. Highly effective treatment is 
available to prevent SCD (Hodgkinson et al., 2016); however, for those individuals who 
may not have been captured through cascade screening, there is a need for an educational 
tool for PCPs to help accurately identify those most at risk. This tool has been identified 
by PCPs to be an important educational piece that would help facilitate the decision-
making process of those most at risk for carrying this mutation, and thus preventing SCD. 
Additionally, the highlighted importance of obtaining multi-generational family histories 
demonstrates the need for PCPs to obtain accurate family histories in order to determine 
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Appendix A: Diagnostic Criteria for ARVC 
 
1994 Task Force of the Working Group Myocardial and Pericardial disease of the 
European Society of Cardiology and the Scientific Council on Cardiomyopathies of 
the International Society and Federation of Cardiology diagnostic criteria 
 Major criteria Minor criteria 
 




Severe dilatation and 
reduction of right 
ventricular ejection 
fraction with no (or only 
mild) LV 
 
Localized right ventricular 
aneurysms (akinetic or 




dilatation of the right 
ventricle 
 
Mild global right 
ventricular 
dilatation and/or ejection 
fraction reduction with 
normal left ventricle 
 
Mild segmental dilatation 
of the right ventricle 
 
Regional right ventricular 
hypokinesia 
 
Tissue characterization of 
walls 








 Inverted T waves in right 
precordial leads (V2 and 
V3) (people aged older 
than 12 years in the 






Epsilon waves or localized 
prolongation (> 11 Oms) 
of the QRS complex in 
right precordial leads (V1-
















extrasystoles (more than 
1000/24 hours on Holter) 
 
Family History Familial disease confirmed 
at necropsy or surgery 
Family history of 
premature sudden death 
(< 35 years) due to 
suspected ARVC 
 
Family history (clinical 
diagnosis based on 
present criteria) 
 
2002 Modification of original task force diagnostic criteria 
ARVC in first degree relative plus one of the following 
ECG 
Signal averaged ECG (SAECG) 
Arrhythmia 
Structural or functional abnormality of the RV 
 
2010 Updated diagnostic criteria 
 Major criteria Minor criteria 
 
Global and/or regional 
dysfunction and structural 
alterations 
By 2D echo: 
-Regional RV akinesia, 
dyskinesia, or aneurysm 
-and 1 of the following 
(end diastole): 
 PLA
X RVOT ≥ 
By 2D echo: 
-Regional RV akinesia or 
dyskinesia 
-and 1 of the following 
(end diastole): 
 PLA































BSA ≥ 110 
mL/m2 
(male) or ≥ 
100 mL/ 
m2 (female) 





By RV angiography: 
-Regional RV akinesia, 
dyskinesia, or aneurysm 






A] ≥ 16 to < 
19 mm/m2) 
 PSA
X RVOT ≥ 




















-and 1 of the following: 
 Rati




BSA ≥ 100 
to < 110 
mL/m2 
(male) or ≥ 









40% to ≤ 
45% 
Tissue characterization of 
walls 
-Residual myocytes < 60% 
by morphometric analysis 
(or < 50% if estimated), 
with fibrous replacement 
of the RV free wall 
myocardium in ≥ 1 
sample, with or without 
fatty replacement of tissue 
on endomyocardial biopsy 
 
-Residual myocytes 60% 
to 75% by morphometric 
analysis (or 50% to 65% 
if estimated), with fibrous 
replacement of the RV 
free wall myocardium in 
≥ 1 
sample, with or without 
fatty replacement of 




-Inverted T waves in right- 
precordial leads (V1, V2, 
and V3) or beyond in 
individuals 
> 14 years of age (in the 
absence of complete right 
bundle-branch block QRS 
≥ 120 ms) 
-Inverted T waves in 
leads V1 and V2 in 
individuals > 14 years of 
age (in the absence of 
complete right bundle-
branch block) or in V4, 
V5, or V6 
 
-Inverted T waves in 
leads V1, V2, V3, and V4 
in individuals > 14 years 







amplitude signals between 
end of QRS complex to 
onset of the T wave) in the 
right precordial leads (V1 
to V3) 
-Late potentials by 
SAECG in ≥ 1 of 3 
parameters in the absence 
of a QRS duration of ≥ 
110 ms on the standard 
ECG 
-Filtered QRS duration 
(fQRS) ≤ 114 ms 
 
-Duration of terminal 
QRS < 40 µV (low-
amplitude signal 






voltage of terminal 40 ms 
≤ 20 µV 
-Terminal activation 
duration of QRS ≥ 55 ms 
measured from the nadir 
of the S wave to the end 
of the QRS, including RꞋ, 




Arrhythmias -Nonsustained or sustained 
ventricular tachycardia of 
left bundle-branch 
morphology with superior 
axis (negative or 
indeterminate QRS in 
leads II, III, and aVF and 
positive in lead aVL) 
-Nonsustained or 
sustained ventricular 
tachycardia of RV 
outflow configuration, 
left bundle-branch block 
morphology with inferior 
axis (positive QRS in 
leads II, III, 
and aVF and negative in 
lead aVL) or of unknown 
axis 
 
- >500 ventricular 
extrasystoles per 24 hours 
(Holter) 
Family History -ARVC/D confirmed in a 
first-degree relative who 




pathologically at autopsy 
or surgery in a first-degree 
relative 
 
-Identification of a 
pathogenic mutation† 
categorized as associated 
or probably associated 
with ARVC/D in the 
patient under evaluation 
-History of ARVC/D in a 
first-degree relative in 
whom it is not possible or 
practical to determine 
whether the family 
member meets current 
Task Force criteria 
 
-Premature sudden death 
(< 35 years of age) due to 




pathologically or by 
current Task Force 


















Appendix C:  Initial Tool 
 
Sudden Cardiac Death caused by ARVC: Information tool for primary physicians 
Purpose 
This brief information tool is designed to provide pertinent and easily accessible 
information about arrhythmogenic right ventricular cardiomyopathy (ARVC) in 
Newfoundland, particularly about the genetic subtype of ARVC (TMEM43, 
p.S358L) which is common in the Province. 
Introduction 
Sudden cardiac death (SCD) in young people (under 40 years) is a devastating event. The 
majority of these early deaths have a genetic component, and may be caused by known 
cardiac genetic disorders such as hypertrophic cardiomyopathy (HCM), dilated 
cardiomyopathy (DCM), catecholaminergic polymorphic ventricular tachycardia (CPVT), 
Long QT syndrome (LQTS) and arrhythmogenic right ventricular cardiomyopathy 
(ARVC)  amongst others. All these conditions are known to have multiple potential 
causative genes. Getting the correct diagnosis is therefore extremely important.   
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
One of the most difficult to clinically diagnose is ARVC. It is usually an autosomal 
dominant disorder where the variability of expression of the disease is extremely wide. As 
a dominant disease, the risk to children from affected parents of inheriting the gene and 
thus the disorder at some point in their lives is 50%.  The clinical diagnosis of ARVC in 
individuals suspected of having the condition requires a set of high level tertiary clinical 




unlikely through probable to definite.  Tragically one of the first symptoms of ARVC can 
be SCD in otherwise healthy individuals and the clinical cardiac testing required is 
inefficient at detecting the disorder. There are multiple genetic subtypes (8 known genes 
to date) thought to cause ARVC.  One of these genetic subtypes is present in 
Newfoundland and responsible for several early deaths in young men. This is the focus of 
this information tool. 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) caused by p.S358L in 
TMEM43 
ARVC caused by the mutation p.S358L in the gene TMEM43 is a common cause of this 
disease and early deaths in Newfoundland and Labrador.  The gene and the causative 
mutation was discovered by Memorial University researchers. It is known to be 
responsible for the deaths of 50% of males who have this mutation before the age of 40 
years (and 80% before the age of 50 years). The equivalent figures in women are 5% and 
20%.  Males are thus affected to a far greater degree than females. It is also a cause of 
heart failure in those who do not die suddenly.  
The change in the gene is a single spelling error. A cytosine nucleotide is changed to a 
thymine, which changes the amino acid serine to a leucine at position 358 in the protein  
TREATMENT 
Recent research from the team has shown that the implantable cardioverter defibrillator 
(ICD) is effective at increasing survival by potentially 30 years in recipients who get the 
ICD based on a mutation test alone. Thus recognising families where this mutation may 




Survival Curves for Males and Females following ICD treatment compared to a 
control group of ancestral family members of the same sex who did not receive an 
ICD. 
  
  MALES     FEMALES 
INSTRUCTIONS: 
What to look for and questions to ask. 
1. Pre syncope and syncope, palpitations, particularly during exercise, and particularly in 
males.  
2. Family history of early SCD. It is very important that family history is NOT restricted 
to first degree relatives. This condition can be present in females who do not present with 
symptoms (although may show some clinical signs on testing) and so the death of a great 
uncle at 25 years where the linkage to the current generation is through females may be 
very significant.  
3.A family history also does not have to be present at all.  
4. Referrals to the Cardiac Genetics clinic (senior cardiologist: Dr. Sean Connors) are 




Appendix D: Recruitment E-mail for Stage 1 
 
Dear Dr. XXXX/Family Medicine Resident, 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a genetic disease with a 
high incidence in Newfoundland and Labrador and is a common cause of young sudden 
cardiac death in otherwise healthy individuals. Early diagnosis significantly increases 
survival. Recognizing high-risk cardiac families for appropriate referral to the 
cardiogenetics service is challenging, but results in massive benefits.       
We have developed a short educational tool to help physicians identify individuals and 
families who might be at risk for ARVC. We need your opinion on whether you find the 
format and accessibility of this tool helpful. We would therefore like to invite you to 
attend a one-hour working lunch at Fill in location on Fill in date at fill in time to discuss 
this new tool and provide feedback to the research team. If you would like to attend this 
working lunch please RSVP to this email so a place can be held for you.  
 We hope this tool will be of help to you and your colleagues in general practice. 
  































Appendix E: Initial survey (May 2016) 
 
Question followed by the total number of responses in that category. The response with 
the majority of responses are highlighted. 
 
1. The tool seems easy to use: 
1-Strongly Disagree;   2-Disagree;   3-Undecided;   4-Agree;   5-Strongly Agree 
 
2. The purpose of the tool was clearly stated: 
1-Strongly Disagree;   2-Disagree;   3-Undecided;   4-Agree;   5-Strongly Agree 
 
3. The instructions were clear: 
1-Strongly Disagree;   2-Disagree;   3-Undecided;   4-Agree;   5-Strongly Agree 
 
4. The layout was easy to follow: 
1-Strongly Disagree;   2-Disagree;   3-Undecided;   4-Agree;   5-Strongly Agree 
 
5. The information was easy to understand: 
1-Strongly Disagree;   2-Disagree;   3-Undecided;   4-Agree;   5-Strongly Agree 
 
6. I feel this tool has increased my knowledge about ARVC in NL: 
1-Strongly Disagree;   2-Disagree;   3-Undecided;   4-Agree;   5-Strongly Agree 
 
7. Overall, this tool would be helpful to me in my practice: 
1-Strongly Disagree;   2-Disagree;   3-Undecided;   4-Agree;   5-Strongly Agree 
 
8. Overall, this tool will help me correctly refer high-risk cardiac families to the genetics 
cardiology service: 
1-Strongly Disagree;   2-Disagree;   3-Undecided;   4-Agree;   5-Strongly Agree 
 
 
Was there important information missing? Please explain 















Appendix F: Revised Version of Tool 
 
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY IN 
NEWFOUNDLAND AND LABRADOR 
AN INFORMATION TOOL FOR PRIMARY CARE PHYSICIANS 
 
2) Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a genetic 
disease that causes ventricular tachycardia (VT), heart failure and sudden 
cardiac death (SCD).  
3) Clinical cardiac testing (12 lead ECG, Holter Monitor, Echocardiography) is 
insensitive in the young. 
4) One of the first symptoms of ARVC may be SCD 
5) Every child born to an ARVC parent has a 50% risk of inheriting ARVC. 
6) There is wide variability of expression of ARVC, so all affected individuals do 
not present in the same way; even those from the same family.  
7) There are many different gene mutations which can cause ARVC. 
8) Several occur in Newfoundland and Labrador(NL). 
 
ONE IMPORTANT TYPE OF ARVC IN NEWFOUNDLAND AND LABRADOR 
 
9) One mutation (p. S358L) in the TMEM43 gene is common in NL and is the 
focus of this information tool 
10) 50% of untreated males with this mutation will die before the age of 40 
years, with 80% dead before 50 years. In females the equivalent figures are 
5% and 20%, respectively. It can also cause heart failure.  
11) Effective treatment is an implantable cardioverter defibrillator (ICD). ICDs 
in the NL population have been found to increase survival by 30 years in 
male mutation carrier ICD recipients. Transplantation is an option following 
heart failure. 
 
Sadly, most families are recognised following the untimely and unexpected death of a young 
adult, which then leads to cascade screening of relatives. 
 
WHAT SHOULD I LOOK FOR IN DETERMINING INDIVIDUALS AT 
RISK FOR ARVC? 
 




Here are some 'RED FLAGS' which should prompt the referral of a family 
1. EARLY DEATHS (under 50 years) due to any cardiac event. 
2. ICDs or heart transplants under 50 years. 
3. Unusual accidental deaths with no contributing factors (e.g. single vehicle automobile 




Of the 160 people in NL who were discovered with this mutation AFTER death, 56% had at least 
one first degree relative 81% had at least one third degree relative with one or more of the 
above Red Flags.  
 
So family history to AT LEAST third degree relatives and across as many generations as are 
available is invaluable.  
 
CLINICAL TESTS 
Often have not been done. On their own, the clinical signs listed below are relatively common 
and may be benign. If however any of the following occur in conjunction with a family history as 
previously described then a referral should be made.   
 
1. 12 lead ECG: poor R-wave progression (PRWP) in the precordial 
leads and premature ventricular contractions (PVCs) in any lead. 
2. ECHOCARDIOGRAPHY: ANY ventricular enlargement 
3. HOLTER MONITOR: PVC's >200 in 24 hours 
 
WHAT GENETIC TESTS CAN BE DONE? 
 
This type of ARVC has genetic testing available at the Health Sciences Centre in St. John's which is 
very quick and at least 99.9% accurate 






Positive: will accelerate cardiac screening tests, treatment and cascade screening for 
family members. 
Negative: the TMEM43 p.S358L mutation has not been detected. 
 
If there was a family history of any of the RED FLAGS alluded to earlier the necessity of 
further testing for the family (to assess other genetic cardiac causes) will be determined 
by the cardiac genetics clinic. 
 
HOW DO I REFER AN AT-RISK PATIENT FOR GENETIC TESTING? 
 
Complete: form Ch-1632: Provincial Medical Genetics Referral 
fax to: (709)777-4190 
Provincial Medical Genetics Program, Cardiac Genetic Clinic 
Attention: Ms. Fiona Curtis, M.Sc., Genetic Counsellor, Eastern Health 
Dr. Sean Connors, MD, D.Phil, FRCPC 
Dr. Kathy Hodgkinson, Ph.D. 
Dr. Anne Williams, MD, FRCPC 















Appendix G: Second Online Survey  
1. The tool seems easy to use 
Strongly Disagree; Disagree; Neutral; Agree; Strongly Agree 
2. The purpose of the tool was clearly stated 
Strongly Disagree; Disagree; Neutral; Agree; Strongly Agree 
3. The instructions were clear 
Strongly Disagree; Disagree; Neutral; Agree; Strongly Agree 
4. The layout was easy to follow 
Strongly Disagree; Disagree; Neutral; Agree; Strongly Agree 
5. The information was easy to understand 
Strongly Disagree; Disagree; Neutral; Agree; Strongly Agree 
6. I feel this tool has increased my knowledge about ARVC in NL 
Strongly Disagree; Disagree; Neutral; Agree; Strongly Agree 
7. Overall, this tool would be helpful to me in my practice 
Strongly Disagree; Disagree; Neutral; Agree; Strongly Agree 
8. Please identify anything you feel is missing, or could be added to the tool, to 
improve it (qualitative question) 
9. Please identify anything you feel is missing, or could be added to the tool, to 
improve it (qualitative question) 
10. Please use this space to provide any other comments or suggestions (qualitative 
question) 
11. Setting of your practice (demographic question) 
12. Location of practice (demographic question) 
13. Years in practice (demographic question) 
14. Age (demographic question) 









Appendix H: Recruitment E-mail to Family Medicine Residents 
Dear Family Medicine Resident, 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a genetic disease with a 
high incidence in Newfoundland and Labrador and is a common cause of young sudden 
cardiac death in otherwise healthy individuals. Early diagnosis significantly increases 
survival. Recognizing high-risk cardiac families for appropriate referral to the 
cardiogenetics service is challenging, but results in massive benefits.  
 
We have developed a short educational tool to help physicians identify individuals and 
families who might be at risk for ARVC. We would like your opinion on whether you find 
the format and accessibility of this tool helpful.  
 
It would be greatly appreciated if you would take a few minutes to view this genetics 
educational tool which is attached to this e-mail and complete the Short Survey. An active 
link for the survey can also be found at the end of the tool. This should take about 10 
minutes of your time.  
 
Please contact Lauren Rickert (llm.rickert@gmail.com), Dr. Kathy Hodgkinson 
(khodgkin@mun.ca), or Dr. Holly Etchegary (holly.etchegary@med.mun.ca) if you have 
any questions.  
 

















Appendix I: Online Advertisement placed by NLMA 
 
Dear Family Physician,  
Newfoundland and Labrador has a higher incidence of Arrhythmogenic Right Ventricular 
Cardiomyopathy (ARVC) than anywhere in Canada. ARVC is a genetic disease whose 
first outcome is often sudden cardiac death.   However, when properly diagnosed, patients 
can benefit greatly from medical management. It is important that physicians can 
recognize high-risk cardiac families and individuals so that they are appropriately referred 
to genetic services.            
  We (Dr's Kathy Hodgkinson and Holly Etchegary, Masters student Lauren Rickert) have 
developed a two-page educational tool to help physicians identify families who are at risk 
for ARVC and need referral to genetics. We would like your opinion on whether you find 
the format and accessibility of the tool helpful. It would be greatly appreciated if you 
would take a few minutes to view the tool (link to tool) and complete the one-page survey 
(link to online survey). This should take about 10 minutes of your time.  
We thank you for your time and input. Please contact Lauren Rickert 
(llm.rickert@gmail.com), Drs. Kathy Hodgkinson (khodgkin@mun.ca), or Holly 



















Appendix J: Recruitment E-mail Distributed by Newfoundland and Labrador 
College of Family Physicians 
 
Dear Family Physician, 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a genetic disease 
with a high incidence in Newfoundland and Labrador and is a common cause of 
young sudden cardiac death in otherwise healthy individuals. Early diagnosis 
significantly increases survival. Recognizing high-risk cardiac families for 
appropriate referral to the cardiogenetics service is challenging, but results in 
massive benefits.  
 
We have developed a short educational tool to help physicians identify individuals 
and families who might be at risk for ARVC. We would like your opinion on 
whether you find the format and accessibility of this tool helpful.  
 
It would be greatly appreciated if you would take a few minutes to view this 
genetics educational tool which is attached to this e-mail and complete the Short 
Survey. An active link for the survey can also be found at the end of the tool. This 
should take about 10 minutes of your time.  
 
Please contact Ms. Lauren Rickert (llm.rickert@gmail.com), Dr. Kathy Hodgkinson 
(khodgkin@mun.ca), or Dr. Holly Etchegary (holly.etchegary@med.mun.ca) if you 
have any questions.  
 















Appendix K: Personal E-mail Sent to Original Working Lunch Participants 
 
Hi Dr.  XX 
In May 2016 you attended a working lunch with myself, Lauren Rickert, and my 
supervisors Drs Kathy Hodgkinson and Holly Etchegary.  
Since that time, we have vastly updated the tool you reviewed in that working lunch, with 
the valuable feed back that was provided. 
I'm writing you today to let you know we have a final draft of the tool completed, and 
since you attended the lunch, wanted to pass that along to you. If you are able, it would be 
greatly appreciated if you could review this version of the tool (attached to this e-mail) 
and complete a short survey, very similar to the one you completed during the working 
lunch (https://s.surveyplanet.com/Bym_glXtG). A link for the survey can also be found at 
the very end of the tool. 
Thank you in advance for your contribution. If you have any further questions or 
comments, please let me know. 
Sincerely, 





















Appendix L: Qualitative Results from Online Survey 
Please identify anything you feel is missing, or could be added to the tool, to improve it 
 How urgent should the referral be? How long will my patient be expected to wait 
to see cardiology or genetics? -P41 
 
 nothing -P37 
 
 Flow chart visual for office would help There is a lot of valuable information 
which is helpful but not a quick reference -P36 
 
 Very busy form - probably not every detail is necessary. A referral form is 
referred to Ch1632 - where to find it? -P35 
 
 one-page screening form with checkboxes. -P26 
 
 Put the form required for a genetics referral at the end of the tool in a format 
which can be printed.-P25  
 
 Most of the information I already knew. But, I might be the odd ball here. It was 
well written, a little long. Single page format would have been best but it is hard 
to do or road map. -P24 
 
 In Newfoundland there are many cases of early ischemic heart disease likely 
linked to diabetes, obesity, hypertension and genetics. So every relative of one of 
these patients should be referred to genetics? I feel that would overwhelm the 
system. -P23 
 
 a schematic or something more visual / flow sheet etc would be helpful doing a 
fhx to 3rd degree relative is not common in FP -P16 
 
 There is nothing missing! I have had several patients with ARVC in my practice 
over the years and this teaching tool is an absolute gem. It is concise, very well 
organized, and flows extremely well. All of the information is there. It's short and 
very sweet. Well done and please keep up the good work, as it is very well 
appreciated. -P15 
 
 Add it to the Med Access list of templates- perhaps ensure that the referral form is 
also available in the Medaccess platform. -P14 
 
 A simple highlight box somewhere on the document could helpful as a quick 





 None. -P11 
 
 Nil -P6 
 
 Nil -P4 
 
Please use this space to provide any other comments or suggestions 
 
• helpful -P37 
 
• Very useful tool-P30 
 




• As already stated in the previous page. -P15 
 
• See previous. -P12 
 
• No patient so far in my practice with his medical issue. -P11 
 
• Nil. Looks good. Would help in practice. Only suggestion, I wonder, would be 
doing a "patient version" that could be given to patients at the same time we are 
using ours as clinicians to get the process started. -P4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
